Author: "C. O'Morain" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"C. O'Morain"' showing total 438 results

Start Over Author "C. O'Morain"

438 results on '"C. O'Morain"'

1. European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan

Author: S. R. Abdulkhakov, D. S. Bordin, R. A. Abdulkhakov, D. D. Safina, A. R. Gizdatullina, L. Z. Gimadieva, G. M. Safina, A. I. Ziyatdinov, A. M. Maturina, O. P. Nyssen, F. Megraud, C. O’Morain, and J. Perez-Gisbert
Subjects: helicobacter pylori, hp-eureg, registry, eradication therapy, bismuth tripotassium dicitrate, Medicine
Abstract: Background. As part of an observational multicenter prospective study European Registry on the management of Helicobacter pylori infection, conducted on the initiative of the European H. pylori and Microbiota Study Group, the compliance of clinical practice in the management of patients with Helicobacter pylori infection in Kazan with clinical guidelines was assessed. Materials and methods. The data of 437 patients included into the register by clinical sites in Kazan in 20132019 were analyzed. The methods used for the initial diagnosis of H. pylori infection and eradication control were evaluated. The frequency of various eradication therapy regimens prescription was analyzed in 379 cases. Data regarding the effectiveness of eradication therapy was analyzed in 173 patients. Results. The rapid urease test (44.2% of cases) and cytology/histology (60% of cases) were most often used for the initial diagnosis of H. pylori infection; however non-invasive methods such as 13C-urea breath (9.2%), serology (6.2%), H. pylori stool antigen test (2.3%) were less common. In 21.7% of patients two methods of H. pylori detection were used for primary diagnosis. The control test to evaluate the effectiveness of eradication therapy at the recommended timepoint was performed in 46.2% of patients. 13C-urea breath test (31.7%), stool PCR/stool antigen test (28.7%), rapid urease test (22.3%), cytology/histology (26.2% of cases) prevailed in the assessment of eradication rate. Standard triple therapy, including proton pump inhibitor, clarithromycin and amoxicillin was most commonly prescribed as first-line therapy (64.6% of cases). The duration of eradication therapy was 14 days in the majority of cases with pantoprazole as the most common proton pump inhibitor in standard triple therapy regimens (84.8%). The efficacy of 14-day standard triple therapy (mITT) was 87.0%. Conclusion. The results indicate a high frequency of non-invasive methods use for assessing the effectiveness of eradication therapy; however, the overall rate of eradication efficacy assessment is low, limiting the possibility of analyzing the eradication results. The effectiveness of the most common 14-day standard triple first-line therapy in Kazan doesnt reach the recommended 90% eradication level. This could be explained by high rate of pantoprazole use, which is not an optimal proton pump inhibitor in eradication therapy regimens.
Published: 2020
Full Text: View/download PDF

2. The role of rifaximin in irritable bowel syndrome derived from a network meta-analysis of randomized control trials

Author: T. Rokkas, Y. Niv, J. Gisbert, F. Franceschi, A. Gasbarrini, G. Hold, C. O'Morain, P. Malfertheiner, and F. Megraud
Subjects: irritable bowel syndrome, rifaximin, dose, network meta-analysis., Diseases of the digestive system. Gastroenterology, RC799-869, Medicine (General), R5-920
Abstract: Objective: Recent randomized control trials (RCTs), have demonstrated the beneficial therapeutic effects of rifaximin for the treatment of the irritable bowel syndrome (IBS). However, in these studies different drug doses have been used and still the optimal therapeutic dose is missing. We aimed to determine rifaximin therapeutic benefit and optimal dose for IBS as evidenced by the results of a network meta-analysis (NWM) of published randomized controlled trials (RCTs). Materials and Methods: PubMed/MEDLINE, EMBASE, and Cochrane Library databases were searched for RCTs investigating the therapeutic effects of rifaximin on IBS through December 2019. Data from each selected RCT were evaluated individually based on an intention-to-treat analysis. A Bayesian NWM was performed to investigate the efficacy rank order of rifaximin therapeutic interventions in IBS. Results: Four eligible studies, including 5 sets of data, were included in this NWM. They included 1,803 IBS patients, randomized to placebo (908 patients), and rifaximin (895 patients). In patients who received rifaximin, four regimens were examined, i.e., (A) = 400 mg tds for 10 days, (B) = 400 mg bid for 10 days, (C) = 550 mg bid for 2 weeks and (D) = 550 mg tds for 2 weeks. The results showed that in IBS rifaximin 400 mg tid for 10 days showed the highest efficacy [SUCRA (surface under cumulative ranking) value 89.5%], in comparison to other rifaximin regimens used and placebo. Conclusions: This NWM showed that the therapeutic efficacy of rifaximin 400 mg tid in IBS patients was greater than that of placebo and the other rifaximin doses studied.
Published: 2020
Full Text: View/download PDF

3. The Effect of Helicobacter pylori antibiotic therapy on the microbiome

Author: A. O’Connor, J. Liou, J. Gisbert, and C. O’Morain
Subjects: h. pylori, microbiome, alpha diversity, beta diversity, antibiotics., Diseases of the digestive system. Gastroenterology, RC799-869, Medicine (General), R5-920
Abstract: The emergence of the microbiome as a significant factor influencing health and disease across a number of organ systems has posed a new challenge for those wishing to identify the optimum treatments for Helicobacter pylori infection. This review aims to address some of these questions. There is a specific concern in the clinical setting about a spectrum of sequelae of this ranging from mild gastrointestinal upset to life-threatening conditions, such as pseudomembranous colitis, as well as overweight and obesity. The literature on the changes induced in the gut microbiota related to H. pylori eradication can be best considered as those which study immediate effects, short-term effects, and long-term effects. Immediate effects usually include decreased bacterial diversity, however, the use of probiotics may reduce the magnitude of change. Studies looking at short term change have consistently shown bacterial diversity to be altered three months after eradication therapy. Most of the long-term studies have shown regression to baseline microbiome diversity after one year, however, this may not be the case for quadruple therapies. Other challenges around the development of antibiotic resistance and the effect of proton pump inhibitors are also discussed.
Published: 2020
Full Text: View/download PDF

4. Comparison of the impact of Helicobacter pylori eradication treatment with bismuth and non-bismuth quadruple regimens on the gut microbiota

Author: S. Prast-Nielsen, A. McNicholl, C. O’Morain, F. Megraud, J. Machado, T. Alarcon, M. Leja, A. Gasbarrini, L. Andersen, L. Engstrand, J. Gisbert, and on behalf European Helicobacter and Microbiota Study Group (EHMSG; www.helicobacter.org)
Subjects: microbiota, antibiotics, clarithromycin, bismuth, proton pump inhibitors, helicobacter pylori., Diseases of the digestive system. Gastroenterology, RC799-869, Medicine (General), R5-920
Abstract: Background: Helicobacter pylori eradication requires a combination of antibiotics. The short and long-term effect of different H. pylori eradication regimens on the gut microbiota has received little attention. Aims: To evaluate and compare the impact of the two most frequently recommended first-line H. pylori eradication regimens — bismuth and non-bismuth quadruple regimens — on the gut microbiota. Patients and Methods: Two 14-day quadruple treatments were evaluated and compared: bismuth-based quadruple therapy (proton pump inhibitor, bismuth, tetracycline, and metronidazole) and non-bismuth quadruple “concomitant” therapy (proton pump inhibitor, amoxicillin, clarithromycin and metronidazole). Stool samples were collected before, and at two and six months after finishing treatment. Gut microbiota was analyzed from the stool samples by sequencing of the 16S rRNA gene and sample-specific barcode sequences. Results: 51 patients were initially included and 38 completed the six months follow-up. A total of 136 stool samples were analyzed. Eradication rates were similar between treatments (bismuth 90%, non-bismuth 89%). Tolerance was also similar. Both treatment regimens induced a significant decrease in alpha diversity two months after treatment, which was partially recovered at six months. Beta diversity was also similarly affected by both treatments and partially recovered at six months follow-up. Longitudinal pairwise Aichison distances were calculated: large individual variation was observed during treatment and at follow-up for both regimens but the average distance was similar, i.e., 1.70 and 1.74, respectively, at two months after treatment, and 1.19 and 1.14 at six months. Statistically significant changes of specific taxa were also observed and these were different for each treatment. Conclusions: H. pylori eradication using quadruple therapies significantly reduces microbiota diversity, although it is partially recovered six months after the end of treatment. No difference was found between bismuth and non-bismuth quadruple therapies; therefore, other aspects should guide prescription.
Published: 2019
Full Text: View/download PDF

5. Evropeyskiy registr Helicobacter pylori (Hp-EuReg): analiz dannykh 2360 bol'nykh, poluchavshikh terapiyu pervoy linii v Rossii

Author: D S Bordin, Yu V Embutnieks, L G Vologzhanina, T A Il'chishina, I N Voinovan, A S Sarsenbaeva, S A Alekseenko, O V Zaitsev, R A Abdulkhakov, M F Osipenko, M A Livzan, V V Tsukanov, S G Burkov, N V Bakulina, N N Dekhnich, L V Tarasova, E Yu Plotnikova, I V Maev, Yu A Kucheryavyi, N V Baryshnikova, M A Butov, S V Kolbasnikov, A L Pakhomova, T V Zhestkova, A Yu Baranovskii, S R Abdulkhakov, E A Ageeva, E A Lyalyukova, A V Vasyutin, N N Golubev, I V Savilova, L V Morkovkina, A G Kononova, F Megraud, C O’Morain, M Ramas, O P Nyssen, A G McNicholl, and J P Gisbert
Subjects: helicobacter pylori, hp-eureg, register, eradication therapy, Medicine
Abstract: On behalf of the scientific Committee and researchers Hp-EuReg European Registry on the management of Helicobacter pylori infection («Hp-EuReg») - a multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group, conducted in 27 European countries in order to evaluate the real clinical practice of diagnosis and treatment of H. pylori and its comparison with international recommendations. Materials and methods. The analysis of 2360 patients entered in the register by the Russian centres of «Hp-EuReg» in 2013-2017, who were underwent 1st line eradication therapy. Results. The most common methods of primary diagnosis of H. pylori are histological (37.7%), rapid urease test (29.2%) and serology (29.7%). The duration of eradication therapy in 9.4% of cases was 7 days, in 65.3% - 10 days, and in 25.3% - 14 days. To control the effectiveness of treatment, H. pylori antigen in feces (31.3%), urea breath test (23.4%) and histological method (23.3%) were used. In 3.6% cases was used serology by mistake. In 17.3% of patients control was not carried out. The effectiveness of triple therapy with a PPI, amoxicillin, clarithromycin (per protocol) was 67.6%, with 7-day course, 81.1% at 10-day and 86.7% at 14-day course. Еradication rate of triple therapy with addition of bismuth (per protocol) reached 90,6% in the group receiving 10-day scheme and 93.6% in the group receiving the 14-day treatment. Conclusion. Significant deviations of clinical practice from expert recommendations, most pronounced at the stage of monitoring the effectiveness of therapy, were noted. The suboptimal efficacy of triple therapy is shown.
Published: 2018
Full Text: View/download PDF

6. Current trends in the treatment of H. pylori infection in Ukraine: results of the European Registry on Helicobacter pylori Management (Hp EuReg)

Author: G. D. Fadieienko, O. V. Shvets, L. Moreira, O. P. Nyssen, F. Mégraud, C. O’Morain, J. P. Gisbert, and O. E. Gridnyev
Subjects: General Medicine
Abstract: Current trends in the treatment of H. pylori infection in Ukraine: results of the European Registry on Helicobacter pylori Management (Hp EuReg) The European Registry on Helicobacter pylori Management (Hp EuReg) was established to evaluate the efficacy and safety of the different eradication H. pylori treatments, as well as to audit H. pylori infection consensus and clinical guidelines implementation. The current study presents data from a sample of patients from Ukraine who were registered in the Hp EuReg until February 2022. The aim was to assess the frequency, effectiveness and safety of treatment against H. pylori infection in Ukraine. Materials and methods. The Hp EuReg, an international multicenter prospective non‑interventional registry, was launched in 2013 and is promoted by the European Helicobacter and Microbiota Study Group (www.helicobacter.org). The Hp EuReg protocol was approved by the Ethics Committee of La Princesa University Hospital (Madrid, Spain) and registered with Clinical Trials.gov under the code NCT02328131. The effectiveness analysis included mainly a modified intention‑to‑treat (mITT) analysis, aiming to mimic the clinical practice outcomes and including all records with a confirmatory test after the eradication treatment, regardless of compliance. Given that some treatment regimens were used only in a small number of patients, only regimens with a relevant number of patients were selected for analyses. Results. Overall 841 patients (54 % women, 46 % men), whose average age (SD) was 48.35 (± 15.52) were included in the register. The main method for diagnosing on‑going H. pylori infection was histology, and the use of urea breath tests and stool antigen tests was low — (approximately 6 % of cases). Assessment of bacterial antibiotic resistance was performed in 13 % of patients, with less than 1 % reporting a positive result. More than half of the patients received quadruple therapy and 40 % triple therapy. Over 90 % of patients were treatment‑ naïve. Almost all patients received low‑dose proton pump inhibitors (PPIs), and a smaller proportion received standard (7.2 %) or high‑dose PPIs (1.2 %). Low‑doses PPI prescriptions negatively affected the effectiveness of therapy: in treatment‑naïve patients’ overall effectiveness was below 85 %, while the use of standard‑ and high‑doses of PPIs achieved 100 % eradication rates in all patients. Despite the fact that the duration of therapy in the vast majority of patients was at least prescribed for 10 days, there were cases (12 %) of administration of 7‑day therapy with the reported suboptimal (< 90 %) effectiveness. In those prescribed with a first‑line treatment of 7 — 10 days, the eradication rate was 82 %, while therapy for 14 days provided 100 % treatment eradication success. In the overall mITT analysis, the use of therapy in naïve patients resulted in the eradication of H. pylori in more than 90 % of patients. It is noteworthy that effectiveness with PPI+ amoxicillin + levofloxacin was below 84 %, suboptimal according to the most up‑to‑date consensus. The administered therapy was well tolerated, which allowed to complete the treatment of more than 90 % of patients, and the incidence of adverse events was less than 4 % in naïve patients, while in patients with repeated courses of therapy it was more than 3 times higher. Conclusions. In Ukraine, the frequency of use of validated non‑invasive methods (urea breath tests and stool antigen test) to detect H. pylori infection is very low. However, Ukrainian doctors often use methods to assess the antibiotic resistance of Helicobacter pylori, which certainly helps to increase the rate of therapy‑guided eradication. The vast majority of eradication therapies administered to patients in the Ukrainian population corresponds to the current guidelines, but very often PPIs were administered in low doses and there were still some cases of regimens lasting 7 days, even in those patients receiving a second‑line therapy, which reduced the treatment effectiveness. Even though overall effectiveness of eradication therapy was over 90 %., there is a need to closely monitor treatment management. Prescribed first‑line therapy was well tolerated by patients — more than 98 % of patients completed treatment.
Published: 2022

7. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases

Author: Ashwin N Ananthakrishnan, Gilaad G Kaplan, Charles N Bernstein, Kristin E Burke, Paul J Lochhead, Alexa N Sasson, Manasi Agrawal, Jimmy Ho Tuan Tiong, Joshua Steinberg, Wolfgang Kruis, Flavio Steinwurz, Vineet Ahuja, Siew C Ng, David T Rubin, Jean-Frederic Colombel, Richard Gearry, M Abreu, V Ahuja, M Allez, A Ananthakrishnan, W Bemelman, C Bernstein, J Braun, Y Chowers, J-F Colombel, S Danese, G D'Haens, A D'Hoore, A Dignass, I Dotan, M Dubinsky, A Ekbom, P Fleshner, C Gasche, MA Gassull, R Gearry, S Ghosh, P Gibson, A Griffiths, J Halfvarson, S Hanauer, N Harpaz, A Hart, T Hibi, M Kamm, G Kaplan, A Kaser, B Korelitz, P Kotze, I Koutroubakis, W Kruis, P Lakatos, J Lewis, J Lindsay, E Loftus, E Louis, M Lukas, F Magro, U Mahadevan, G Mantzaris, J-Y Mary, D McGovern, B Moum, P Munkholm, M Neurath, S Ng, C O'Morain, T Oresland, R Panaccione, J Panes, Y Panis, J Pemberton, L Peyrin-Biroulet, C Prantera, D Rachmilewitz, Z Ran, W Reinisch, F Remzi, J Rhodes, R Riddell, G Rogler, D Rubin, D Sachar, W Sandborn, B Sands, B Sartor, J Schoelmerich, S Schreiber, C Siegel, B Siegmund, M Silverberg, J Söderholm, A Sood, A Spinelli, E Stange, F Steinwurz, S Targan, S Travis, D Turner, C Tysk, M Vatn, S Vermeire, M Watanabe, T Yamamoto, and J Yamamoto-Furusho
Subjects: Consensus, Hepatology, Crohn Disease, Gastroenterology, Humans, Colitis, Ulcerative, Inflammatory Bowel Diseases, Life Style
Abstract: Environmental and lifestyle factors play an important role in the natural history of Crohn's disease and ulcerative colitis. A group of international experts from the International Organization for the Study of Inflammatory Bowel Diseases voted on a series of consensus statements to inform the management of inflammatory bowel disease (IBD). The recommendations include avoiding traditional cigarette smoking in patients with Crohn's disease or ulcerative colitis, screening for symptoms of depression, anxiety, and psychosocial stressors at diagnosis and during flares (with referral to mental health professionals when appropriate), and encouraging regular physical activity as tolerated. Patients using dietary approaches for treatment of their IBD should be encouraged to adopt diets that are best supported by evidence and involve monitoring for the objective resolution of inflammation. We recommend formal assessment for obesity and nutritional deficiencies, and patients should be encouraged to maintain a normal body-mass index. A shared decision-making approach to contraception should include the consideration of IBD-related factors, and risk factors for venous thromboembolism. Long-term or frequent use of high-dose non-steroidal anti-inflammatory drugs should be avoided. For primary prevention of disease in the offspring of patients with IBD, we recommend avoiding passive exposure to tobacco, using antibiotics judiciously, and considering breastfeeding when able.
Published: 2022

8. Role of the proton pump inhibitors in Helicobacter pylori eradication: results from the European registry on H. pylori management (HP-EUREG)

Author: M. Castro Fernandez, M. Pabón-Carrasco, A. Keco- Huerga1, Á. Pérez-Aísa, D. Vaira, L. Jonaitis, B. Tepes, D. Bordin, A. Lucendo, L. Vologzhanina, L. Bujanda, N. Brglez Jurecic, A. Lanas, M. Leja, E. Mammadov, U. Mahmudov, M. Caldas, L. Rodrigo, F. Lerang, G. Fadieienko, R. Abdulkhakov, J.M. Huguet Malavés, O. Zaytsev, T. Ilchishina, L. Fernández- Salazar, A. Silkanovna Sarsenbaeva, I. Bakulin, A.G. Gravina, M. Perona, S. Alekseenko, J. Barrio, M. Areia, Ó. Nuñez, P. Bogomolov, B.J. Gomez Rodriguez, M. Dominguez-Cajal, J. Gomez Camarero, S. Georgopoulos, P. Almela Notari, Ante Tonkić, R. Pellicano, H. Simsek, L. Kunovský, A. Gasbarrini, J.M. Botargues Bote, I. Puig, O. Perez Nyssen, F. Mégraud, C. O’Morain, J. P. Gisbert
Subjects: Helicobacter pylori, proton pump inhibitors
Abstract: Introduction: Management of Helicobacter pylori infection (H. pylori) re-quires co- treatment with proton pump inhibitors (PPIs) and the use of an- tibiotics to achieve successful eradicationAims & Methods: To evaluate the role of PPIs in the eradication of H. py-lori, based on the “European Registry onHelicobacter pylori Management” (Hp- EuReg).The Hp-EuReg is a multicentre, prospective, non-interventional, registry assessing decisions and outcomes of H. pylori management by European gastroenterologists in routine clinical practice. Countries recruiting more than 1, 000 patients were included. Effectiveness was assessed by modi- fied intention-to-treat (mITT). Data were quality reviewed.Results: Overall, 22, 078 patients from 5 countries were analysed. Optimal (»90%) first-line mITT effectiveness was achieved with the following treatments: 14-day clarithromycin- amoxicillin- bismuth quadruple therapy, and 14- day metronidazole-tetracycline-bismuth quadruple therapy, both inde-pendently of the PPI dose prescribed ; in all 10- or 14-day therapies with high-dose PPIs (except with standard 10-day triple therapy) ; in 10-day se-quential and 10- day quadruple clarithromycin-amoxicillin- bismuth, and 10-day quadruple metronidazole- tetracycline- bismuth with standard-dose PPIs. None of the 7-day therapies achieved optimal cure rates re-gardless of the PPI dose used. The PPI dose was significantly associated with the effectiveness of: 10- or 14- day standard triple and quadruple con-comitant therapies, and 10-day quadruple sequential and metronidazole-tetracycline-bismuth therapies. Table 1 details the mITT effectiveness by duration and PPI dose used.Conclusion: In first-lineH. pylori treatment, ≥90% effectiveness is obtained with standard-dose PPIs in 10-day sequential and 10- or 14-day bismuth quadruple therapies and with high-dose PPIs in all 10- or 14-day therapies except with standard 10-day triple therapy.
Published: 2022

9. Empirical first-line treatment use and effectiveness trends in Europe in the period 2013- 2021: results from the European registry on H. pylori management (HP-EUREG)

Author: O. Perez Nyssen, Á. Pérez-Aísa, D. Vaira, L. Jonaitis, B. Tepeš, D.S. Bordin, M. Castro- Fernández, A.J. Lucendo, L. Vologzhanina, L. Bujanda Fernández de Piérola, M. Denkovski, A. Lanas, M. Leja, G. Babayeva, U. Mahmudov, L. Rodrigo, F. Lerang, G. Fadieienko, R.A. Abdulkhakov, J.M. Huguet Malavés, O. Zaytsev, T. Ilchishina, L. Fernández-Salazar, A. Sarsenbaeva, I. Bakulin, A.G. Gravina, M. Perona, S. Alekseenko, J. Barrio, M. Areia, O. Núñez Martínez, P. Bogomolov, B.J. Gómez Rodríguez, M. Domínguez-Cajal, J. Gómez Camarero, S. Georgopoulos, P. Almela Notari, A. Tonkić, R. Pellicano, H. Şimşek, L. Kunovský, A. Gasbarrini, J.M. Botargues Bote, G.M. Buzás, M. Fernandez- Bermejo, L. Moreira, I. Puig, F. Mégraud, C. O’Morain, J.P. Gisbert
Subjects: Helicobacter pylori
Abstract: Introduction: The impact of consensus, prescription choices and efficacy trends on clinical practice over time has not been studied in depth.Aims & Methods: International multicenter prospective non-intervention-al registry aimed to evaluate the decisions and outcomes of H. pyloriman-agement by European gastroenterologists. All infected adult patients were systematically registered at AEG-REDCap e-CRF from 2013 to December 2021. Variables included: previous eradication attempts, prescribed treatment, adverse events, and outcomes. Modified intention- to-treat (mITT) and time trend analyses were performed. Data were subject to quality review.Results: So far 49, 739 patients from 29 European countries have been in-cluded, and 35, 203 (71%) were first-line empirical prescriptions. Overall, the most common prescribed treatments in the 2013-21 period were triple therapies ; however, a shift in antibiotic regimens was identi-fied. Triple therapies decreased from over 50% of prescription in 2013/15 to less than 25% in 2020/21 ; likewise, non-bismuth concomitant therapy use decreased from 21% in 2013/14 to 13% in 2020/21, while three-in-one single- capsuleincreased from 0- 1% in 2014/2015 to 17% in 2020/21. An increase in the average duration of treatments from 9.8 days in 2013 to 13 days in 2021 was identified, as well as the daily high- dose of PPIs increasing from 16% in 2013 to 50% in 2021. Detailed description of most common treatments is shown in Table 1. Re-garding the effectiveness of each specific treatment, no trend was identi-fied (data now shown) ; however, there was a 10% overall improvement in first-line mITT overall effectiveness from 2013 to 2021. Conclusion: European gastroenterological practice is constantly adapting to the newest published evidence and recommendations (reducing the use of triple therapies and increasing both the duration of treatment and the dose of PPIs), with a subsequent progressive improvement in overall effectiveness.
Published: 2022

10. Effectiveness of treatments against Helicobacter pylori according to resistance to clarithromycin: data from the European registry on Helicobacter pylori management (HP-EUREG)

Author: L. Bujanda Fernández de Piérola, O. Perez Nyssen, J. Ramos, D.S. Bordin, B. Tepeš, Á. Pérez-Aísa, B. Vaira, M. Caldas Álvarez, M. Castro Fernandez, F. Lerang, M. Leja, L.R. Rodrigo Sáez, T. Rokkas, L. Kupcinskas, J. Perez-Lasala, L. Jonaitis, O. Shvets, A. Gasbarrini, I. Simsek, P. Phull, G.M. Buzás, J.C.L. Machado, Y. Niv, L. Boyanova, E.D. Dobru, V. Lamy, Ante Tonkić, W. Marlicz, C. Beglinger, M. Venerito, P. Bytzer, L. Capelle, T. Milosavljevic, L. Vologhzanina, G. Fadeenko, G. Fiorini, E. Resina Sierra, R. Muñoz González, A. Cano-Catalá, I. Puig, F. Mégraud, C. O‘Morain, J. Gisbert
Subjects: Helicobacter pylori, clarithromycin, resistance
Abstract: Introduction: Antibiotic resistance is the main factor influencing the ef-ficacy of treatments to eradicate the infection by Helicobacter pylori (H. pylori). The treatments including clarithromycin are the most frequently used in first-line ; however, the bacterial resistance to clarithromycin in treatment-naïve patients in Europe is, overall, >20%.Aims & Methods: To assess the effectiveness of first-line H. pylori treat- ments in Europe according to the resistance to clarithromycin.Non-interventional, prospective, multicenter, international European re-gistry on the management of H. pylori (Hp-EuReg). All culture-diagnosed infected adult patients were registered at AEG-REDCap e-CRF from 2013 to 2021. Per-protocol (PP) analysis was performed based on the presence or absence of bacterial resistance to clarithromycin in treatment-naïve pati-ents. The data was subject to quality control.Results: In total, 2, 479 culture-naïve patients were included. Of these, 627 (25%) reported resistance to clarithromycin. The eradication rate with the standard triple therapy (PPI+clarithromycin+amoxicillin) in patients susceptible to clarithromycin was 92% (424/460). The eradication rate in these clarithromycin-susceptible patients was higher both with the con-comitant regimen (PPI+clarithromycin+amoxicillin+metronidazole) and with the sequential treatment with tinidazole (95%, 882/929), and also with the bismuth quadruple regimen (PPI+bismuth+tetracycline+metronidazole) as single capsule (100%, 67/67) (p
Published: 2022

11. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis

Author: George Karamanolis, Trygve Hausken, A. Sheptulin, A Papathanasopoulos, Jan Tack, Daniel Keszthelyi, M. Corsetti, T. Milosavljevic, Frank Zerbib, M. Storr, Dan L. Dumitrascu, A. Stengel, Hans Törnblom, Tim Vanuytsel, Giovanni Sarnelli, C. Malagelada, H. De Schepper, Lucas Wauters, Daniel Pohl, Agata Mulak, Ram Dickman, Goran Hauser, D. Rumyantseva, Giovanni Barbara, Jordi Serra, N. Zarate, C. O'Morain, Benoit Coffin, Guillaume Gourcerol, Anne Farmer, Serhat Bor, Vasile Drug, M. Velosa, Annemieke Smet, Edoardo Savarino, Jolien Schol, Paul Enck, M. Waluga, Anna Accarino, O. Storonova, Sarnelli, G., Schol J., Wauters L., Dickman R., Drug V., Mulak A., Serra J., Enck P., Tack J., Barbara G., Interne Geneeskunde, RS: NUTRIM - R2 - Liver and digestive health, and MUMC+: MA Maag Darm Lever (9)
Subjects: Serotonin 5-HT4 Receptor Antagonists, Gastroparesis, gastroparesi, Delphi Technique, Physiology, consensus, endoscopy, gastric emptying, gastroparesis, guideline, prokinetic, Gastroenterology, Endoscopy, Gastrointestinal, 0302 clinical medicine, Quality of life, Risk Factors, QUALITY-OF-LIFE, Epidemiology, Endoscopy, Digestive System, Societies, Medical, DIABETIC GASTROPARESIS, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, Nutritional Support, Nausea, Neurogastroenterology, Postprandial Period, Serotonin Receptor Agonists, Europe, Dopamine D2 Receptor Antagonists, Oncology, Neurology, 030220 oncology & carcinogenesis, Vomiting, 030211 gastroenterology & hepatology, medicine.symptom, Symptom Assessment, HEALTH-CARE UTILIZATION, Life Sciences & Biomedicine, Human, medicine.medical_specialty, GASTRIC ELECTRICAL-STIMULATION, Consensus, THERAPY IMPROVES SYMPTOMS, LONG-TERM, IDIOPATHIC GASTROPARESIS, Consensu, 03 medical and health sciences, Dopamine D2 Receptor Antagonist, Internal medicine, medicine, Humans, Dyspepsia, Intensive care medicine, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, TERM-FOLLOW-UP, GASTROINTESTINAL SYMPTOMS, Science & Technology, Gastric emptying, Gastroenterology & Hepatology, Endocrine and Autonomic Systems, business.industry, Risk Factor, Guideline, medicine.disease, Gastric Emptying, Serotonin Receptor Agonist, Quality of Life, FUNCTIONAL DYSPEPSIA, business, Diet Therapy
Abstract: BACKGROUND: Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. METHODS: A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements. RESULTS: The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine-2 antagonists and 5-HT4 receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long-term prognosis of gastroparesis depends on the cause. CONCLUSIONS AND INFERENCES: A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis. ispartof: UNITED EUROPEAN GASTROENTEROLOGY JOURNAL vol:9 issue:3 pages:287-306 ispartof: location:England status: published
Published: 2021

12. Consensus Guidelines: Agreement and Debate Surrounding the Optimal Management of Helicobacter pylori Infection

Author: D McNamara and C O’Morain
Subjects: Diseases of the digestive system. Gastroenterology, RC799-869
Abstract: Helicobacter pylori is a recognized cause of a variety of gastroduodenal pathology. The high prevalence of both H pylori infection and related diseases within the community warrants its consideration as a public health care issue. The availability of reliable and safe noninvasive diagnostic techniques coupled with the development of effective and tolerable treatments has enabled primary health care personnel to manage this infection actively. The role of the primary care physician in the future management of H pylori infection is thus of central importance. The wealth of evidence produced by over 15 years of research into H pylori has expanded the list of disease associations and treatment benefits as well as elucidated the pathophysiological mechanisms involved. As a result, there has been a growing need to harmonize this information with clinical practice and to provide direction for the appropriate management by both specialists and general practitioners. Several national guidelines have been produced. The areas relating to H pylori infection that they considered and their recommendations vary. In 1994, the National Institutes of Health produced globally accepted recommendations for the management of H pylori-related peptic ulceration. The broader role of H pylori as a gastroduodenal pathogen and a public health care issue was not addressed. Recently, European and Canadian consensus guidelines have been published that identified overall management issues, including the role of primary and specialist care, and considered the appropriateness of employing eradication therapy for the spectrum of conditions in which H pylori has a direct or indirect association based on the available information. These guidelines, while in agreement regarding many issues, differ considerably in their recommendations for primary health care and regarding central issues such as the management of dyspepsia and gastric cancer. Some variations may reflect differing health care structures as well as the prevalence of both infection and associated diseases. However, the interpretation of evidence produced by recent research contributes to their conflicting statements.
Published: 2000
Full Text: View/download PDF

13. OC.08.2 EFFECTIVENESS OF EMPIRICAL FIRST-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Author: Francis Mégraud, Francesco Franceschi, M. Ghisa, Luigi Gatta, Javier P. Gisbert, L. Granata, Fabio Farinati, Matteo Pavoni, Alessandro Gasbarrini, Olga P Nyssen, I.M. Saracino, Rinaldo Pellicano, Alice Di Rocco, A. Di Leo, Maria Pina Dore, Mary Romano, Dolores Vaira, C. O'Morain, Antonietta Gerarda Gravina, Giuseppe Losurdo, G. Nardone, Giulia Fiorini, and Ignasi Puig
Subjects: medicine.medical_specialty, Second line, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business
Published: 2021

14. Empirical first-line treatment use and effectiveness trends in Europe in the period 2013- 2020: results from the European registry on H. pylori management (HP-EUREG)

Author: O. P. Nyssen , Á. Pérez-Aísa , D. Vaira , L. Jonaitis , B. Tepes , A. Keco-Huerga , M. Castro- Fernández , A. Lucendo , D. Bordin , N. Brglez Jurecic , L. Vologzhanina, M. Caldas , G. Fadieienko, R. Abdulkhakov, L. Bujanda, M. Leja, M. Romano, S. Georgopoulos, Ante Tonkić, H. Simsek, A. Gasbarrini, G. M Buzas, P. Phull, M. Venerito, P. Malfertheiner, J. Kupčinskas , G. Babayeva, O. Shvets, F. Lerang, R. Marcos Pinto, T. Rokkas, I. Simsek, S. Smith, Y. Niv, D. Lamarque, F. Heluwaert, A. Goldis, W. Marlicz, V. Milivojevic, L. Boyanova, L. Kunovský, V. Lamy, C. Beglinger, P. Bytzer, L. Capelle, I. Puig, F. Mégraud, C. O’Morain, J. P. Gisbert
Subjects: Helicobacter pylori
Abstract: Background: The impact of consensus, prescription choices and efficacy trends on clinical practice over time has not been studied in depth. Methods: International multicenter prospective non-interventional registry aimed to evaluate the decisions and outcomes of H. pylori management by European gastroenterologists. All infected adult patients were registered at AEG-REDCap e-CRF up to February 2021. Modified intention-to-treat (mITT) and time trend analyses were performed. Results: So far 29, 634 first-line empirical prescriptions from 31 European countries have been included. Overall, the most common prescribed treatments in the 2013-20 were triple therapies ; however, a shift in antibiotic regimens was identified. Triple therapies decreased from over 50% of prescription in 2013/15 to less than 20% in 2018/20. Non- bismuth concomitant therapy use decreased from 21% in 2013/14 to 13% in 2019/20, while Pylera® increased from 0-1% in 2014/2015 to 19% in 2019/20. An increase in the average duration of treatments from 11 to 13 days in 2013-2020, and of the daily dose of PPI, was identified (No trend was identified (data now shown) ; however, there was an 8% overall improvement in first-line mITT overall effectiveness from 2013 to 2020 (Table 1). Conclusions: European gastroenterological practice is constantly adapting to the newest published evidence and recommendations (reducing the use of triple therapies and increasing the duration of treatment and the dose of PPIs), with a subsequent progressive improvement in overall effectiveness.
Published: 2021

15. First-line empirical H. pylori eradication therapy in Europe: results from 30,000 cases of the European registry on H. pylori management (HP- EUREG)

Author: O. P. Nyssen, Á. Pérez-Aísa, D. Vaira, L. Jonaitis, B. Tepeš, A. Keco-Huerga, M. Castro Fernández, A. Lucendo, D. Bordin, N. Brglez Jurecic, L. Vologzhanina, M. Caldas, G. Fadieienko, R. Abdulkhakov, L. Bujanda, M. Leja, M. Romano, S. Georgopoulos, V. Ntouli, Ante Tonkić, H. Simsek, A. Gasbarrini, G. M Buzas, P. Phull, M. Venerito, P. Malfertheiner, J. Kupčinskas, G. Babayeva, O. Shvets, F. Lerang, R. Marcos Pinto, T. Rokkas, I. Ilkay Simsek, S. Smith, Y. Niv, D. Lamarque, F. Heluwaert, A. Goldis, W. Marlicz, V. Milivojevic, L. Boyanova, L. Kunovský, V. Lamy, C. Beglinger, P. Bytzer, L. Capelle, I. Puig, F. Mégraud, C. O’Morain, J. P. Gisbert
Subjects: Helicobacter pylori, eradication therapy
Abstract: Introduction: The best approach for Helicobacter pylori management re-mains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care.Aims & Methods: International multicentre prospective non-intervention-al registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap up to February 2021. Variables in-cluded: demographics, previous eradication attempts, prescribed treat-ment, adverse events, and outcomes. Modified intention-to-treat (mITT) and per-protocol (PP) analyses were performed and data were subject to quality review to ensure information reliability.Results: In total 41, 562 patients from 31 European countries were evaluat-ed and 29, 634 (70%) first-line empirical H. pylori treatments were included for analysis. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), followed by non-bismuth concomitant treat-ment (18%) and bismuth quadruple (three-in-one single capsule) (12%), achieving 84%, 90% and 94% mITT eradication rate, respectively. Over 90% effectiveness was obtained only with 10 and 14-day bismuth quadru- ple or with 14-day concomitant treatment (Table). Longer treatment dura-tion, higher acid inhibition and compliance were associated with higher eradication rates. Conclusion: Management of H. pylori infection by European gastroenter-ologists is heterogeneous. Only quadruple therapies lasting at least ten days are able to achieve over 90% eradication rates.
Published: 2021

16. Empirical second-line treatments in Europe: results from the European registry on H. pylori management (HP-EUREG)

Author: O. P. Nyssen , Á. Pérez-Aísa , D. Vaira , G. Fiorini , L. Rodrigo , A. Keco-Huerga , M. Castro- Fernández , J. Kupčinskas , L. Jonaitis , B. Tepes , L. Vologzhanina , M. Caldas , S. Martinez- Dominguez , E. Alfaro , A. Lucendo, L. Bujanda, T. Di Maira, J. Barrio, J. M. Huguet, J. Perez Lasala, D. Bordin, M. Leja, A. Gasbarrini, S. Georgopoulos, F. Lerang, P. Phull, T. Rokkas, O. Shvets, Y. Niv, D. Lamarque, F. Heluwaert, Ante Tonkić, M. Venerito, I. Simsek, V. Milivojevic, G. M Buzas, V. Lamy, W. Marlicz, L. Boyanova, P. Bytzer, L. Capelle, L. Kunovský, A. Goldis, C. Beglinger, M. Espada , I. Puig, F. Mégraud, C. O’Morain, J. P. Gisbert
Subjects: Helicobacter pylori
Abstract: Background: After a first eradication attempt, approximately 10-20% of patients will fail to achieve H. pylori eradication. Aims: To evaluate the effectiveness of second-line empirical treatments. Methods: A systematic prospective registry of the clinical practice of European gastroenterologists (31 countries) on H. pylori management was established. All infected adult patients were systematically registered at AEG-REDCap e-CRF until February 2021. Modified intention-to-treat (mITT) and per- protocol (PP) analyses were performed. Results: Overall, 5, 228 patients received a second-line empirical therapy. Overall effectiveness was 84% (both by mITT and PP). Over 97% of patients were compliant. AEs were reported in 28% of the cases. Most frequent second-line prescriptions and effectiveness per antibiotic combination is shown in table 1. After failure of first-line clarithromycin-containing treatment, optimal eradication (>90%) was obtained with moxifloxacin-containing triple therapy, or quadruple therapy with levofloxacin and bismuth. In patients receiving triple regimens containing levofloxacin or moxifloxacin and levofloxacin-bismuth quadruple regimens, cure rates were optimized with 14-day regimens using high doses of proton pump inhibitors (PPIs). However, Pylera® or quadruple therapy with levofloxacin and bismuth achieved consistent eradication rates regardless of the PPI dose, duration of therapy, or previous firstline treatment regimen. Conclusion: Empirical second-line regimens including either 14-day triple therapies with levofloxacin or moxifloxacin, or 14-day levofloxacin-bismuth quadruple or 10-day bismuth quadruple therapies provided optimal effectiveness. However, many other second-line treatments evaluated reported low eradication rates.
Published: 2021

17. H. pylori diagnostic tests used in naïve patients: results from the European Registry on H. pylori management (Hp-EuReg)

Author: I. Puig , D. Bordin , A. Gasbarrini , B. Tepes , F. Lerang , G. Babayeva , T. Rokkas , M. Leja , J. Kupčinskas , R. M. Pinto, Ante Tonkić, S. Smith, H. Simsek, G. M. Buzas, P. Phull, O. Shvets, M. Venerito, D. Lamarque, Y. Niv, V. Milivojevic, A. Cano , O. P. Nyssen, F. Mégraud, C. O’Morain, J. P. Gisbert
Subjects: Helicobacter pylori, naïve patients
Abstract: Background: Clinical guidelines recommend the “test and treat” strategy in young patients without alarm symptoms. Objective: To evaluate the type of tests used for the diagnosis of H. pylori infection in naïve patients in Europe. Methods: International multicentre prospective European Registry on H. pylori Management (Hp- EuReg) collecting all adult patients where a diagnostic test was used were registered at AEG- REDCap e-CRF until February 2021. Results: In total, 27, 776 naïve patients from 20 European countries were included in the analysis (61% female, 47%
Published: 2021

18. First-line H. pylori eradication therapy in Europe: Results from 24,882 cases of the European Registry on H. pylori Management(Hp-EuReg)

Author: O. P. Nyssen, D. Bordin, B. Tepes, A. Pérez-Aisa, D. Vaira, M. Caldas, L. Bujanda, M. Castro- Fernandez, F. Frode Lerang, M. Leja, L. Rodrigo, T. Rokkas, L. Kupcinskas, J. Pérez-Lasala, L. Jonaitis, O. Shvets, A. Gasbarrini, H. Simsek, A. T. R Axon, G. M. Buzás, J. Machado, Y. Niv, L. Boyanova, A. Goldis, V. Lamy, Ante Tonkić, K. Przytulski, C. Beglinger, M. Venerito, P. Bytzer, L. G. Capelle, T. Milosavljevic, V. Milivojevic, L. Veijola, J. Molina-Infante, L. Vologzhanina, G. Fadeenko, I. Ariño, G. Fiorini, A. Garre, J. Garrido, C. F. Pérez, F. Heluwaert, I. Puig, F. Mégraud, C. O'Morain, and J. P. Gisbert
Subjects: Helicobacter pylori, eradication therapy
Abstract: Background: The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. Design: International multicentre prospective non- interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap up to April 2020. Variables included: demographics, previous eradication at-tempts, prescribed treatment, adverse events, and outcomes. Modified intention-to-treat (mITT) and per- protocol (PP) analyses were performed and data were subject to quality review to ensure information reliability. Results: In total 36, 319 patients from 29 European countries were evaluated and 24, 882 (70%) first-line empirical H. pylori treatments were included for analysis. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (40%), followed by concomitant treatment (19%) and bismuth quadruple (Pylera®) (10%) achieving 83%, 91% and 95% mITT eradication rate, respectively. Over 90% effectiveness was obtained only with 10 and 14-day bismuth quadruple or 14-day concomitant treatment. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Conclusions: Management of H. pylori infection by European gastroenterologists is heterogeneous. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates.
Published: 2020

19. European Registry on H. pylori Management (Hp EuReg): Empirical firstline treatment use and effectiveness trends in Europe in the period 2013 2020

Author: O. P. Nyssen, D. Bordin, B. Tepes, A. Pérez-Aisa, D. Vaira, M. Caldas, L. Bujanda, M. Castro- Fernandez, F. Frode Lerang, M. Leja, L. Rodrigo, T. Rokkas, L. Kupcinskas, J. Pérez-Lasala, L. Jonaitis, O. Shvets, A. Gasbarrini, H. Simsek, A. T. R Axon, G. M. Buzás, J. Machado, Y. Niv, L. Boyanova, A. Goldis, V. Lamy, Ante Tonkić, K. Przytulski, C. Beglinger, M. Venerito, P. Bytzer, L. G. Capelle, T. Milosavljevic, L. Veijola, J. Molina-Infante, L. Vologzhanina, G. Fadeenko, I. Ariño, G. Fiorini, A. Garre, J. Garrido, C. F. Pérez, F. Heluwaert, I. Puig, F. Mégraud, C. O'Morain, and J. P. Gisbert
Subjects: Helicobacter pylori
Abstract: Background: The impact of consensus, prescription choices and efficacy trends on clinical practice over time has not been studied in depth. Methods: International multicenter prospective non- interventional registry aimed to evaluate the decisions and outcomes of H. pylori management by European gastroenterologists. All infected adult patients were registered at AEG-REDCap e-CRF up to April 2020. Modified intention-to-treat (mITT) and time trend analyses were performed. Results: So far 24, 882 first-line empirical prescriptions from 29 European countries have been included. Overall, the most common prescribed treatments in 2013-20 were triple therapies ; however, a shift in antibiotic regimens was identified. Triple therapies decreased from >50% of prescription in 2013/15 to less than 20% in 2018/20 ; concomitant therapy decreased from 21% in 2013/14 to 13% in 2019/20, while Pylera® increased from 0-1% in 2014/2015 to 18% in 2018/20. An increase in the average duration of treatments from 10.9 days in 2013 to 12.0 in 2020, and of the daily dose of PPI was identified. No trend was identified regarding the effectiveness of each specific treatment (data now shown) ; however, an overall 5% improvement in first-line mITT effectiveness was observed. Conclusions: European gastroenterological practice is constantly adapting to the newest published evidence and recommendations (reducing the use of triple therapies and increasing the duration of treatment and the dose of PPIs), with a subsequent improvement in overall effectiveness.
Published: 2020

20. OC.08.4 ANTIBIOTIC RESISTANCE TRENDS OF ITALIAN H. PYLORI NAÏVE PATIENTS BETWEEN 2013-2020: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Author: G. Nardone, Fabio Farinati, Giuseppe Losurdo, Giulia Fiorini, Antonietta Gerarda Gravina, Alice Di Rocco, Ignasi Puig, M. Francis, Maria Pina Dore, Olga P Nyssen, Javier P. Gisbert, Alessandro Gasbarrini, Matteo Pavoni, M. Ghisa, A. Di Leo, Dolores Vaira, I.M. Saracino, Maurizio Romano, L. Granata, Rinaldo Pellicano, Luigi Gatta, C. O'Morain, and Francesco Franceschi
Subjects: Therapy naive, medicine.medical_specialty, Antibiotic resistance, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business
Published: 2021

21. OC.08.5 EFFECTIVENESS OF EMPIRICAL SECOND-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Author: L. Gatta, G. Fiorini, I.M. Saracino, M. Pavoni, M. Romano, A.G. Gravina, L. Granata, R. Pellicano, A. Gasbarrini, A. Di Leo, G. Losurdo, F. Franceschi, G. Nardone, A. Rocco, M.P. Dore, F. Farinati, M. Ghisa, I. Puig, O. Nyssen, M. Francis, C. O'Morain, D. Vaira, and J. Gisbert
Subjects: Hepatology, Gastroenterology
Published: 2021

22. European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia

Author: D S, Bordin, Yu V, Embutnieks, L G, Vologzhanina, T A, Il'chishina, I N, Voinovan, A S, Sarsenbaeva, S A, Alekseenko, O V, Zaitsev, R A, Abdulkhakov, M F, Osipenko, M A, Livzan, V V, Tsukanov, S G, Burkov, N V, Bakulina, N N, Dekhnich, L V, Tarasova, E Yu, Plotnikova, I V, Maev, Yu A, Kucheryavyi, N V, Baryshnikova, M A, Butov, S V, Kolbasnikov, A L, Pakhomova, T V, Zhestkova, A Yu, Baranovskii, S R, Abdulkhakov, E A, Ageeva, E A, Lyalyukova, A V, Vasyutin, N N, Golubev, I V, Savilova, L V, Morkovkina, A G, Kononova, F, Megraud, C, O'Morain, M, Ramas, O P, Nyssen, A G, McNicholl, and J P, Gisbert
Subjects: Europe, Helicobacter pylori, Clarithromycin, Amoxicillin, Humans, Drug Therapy, Combination, Proton Pump Inhibitors, Prospective Studies, Registries, Anti-Bacterial Agents, Helicobacter Infections
Abstract: European Registry on the management of Helicobacter pylori infection («Hp-EuReg») - a multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group, conducted in 27 European countries in order to evaluate the real clinical practice of diagnosis and treatment of H. pylori and its comparison with international recommendations.The analysis of 2360 patients entered in the register by the Russian centres of «Hp-EuReg» in 2013-2017, who were underwent 1st line eradication therapy.The most common methods of primary diagnosis of H. pylori are histological (37.7%), rapid urease test (29.2%) and serology (29.7%). The duration of eradication therapy in 9.4% of cases was 7 days, in 65.3% - 10 days, and in 25.3% - 14 days. To control the effec- tiveness of treatment, H. pylori antigen in feces (31.3%), urea breath test (23.4%) and histological method (23.3%) were used. In 3.6% cases was used serology by mistake. In 17.3% of patients control was not carried out. The effectiveness of triple therapy with a PPI, amoxicillin, clar- ithromycin (per protocol) was 67.6%, with 7-day course, 81.1% at 10-day and 86.7% at 14-day course. Eradication rate of triple therapy with addition of bismuth (per protocol) reached 90,6% in the group receiving 10-day scheme and 93.6% in the group receiving the 14-day treatment.Significant deviations of clinical practice from expert recommendations, most pronounced at the stage of monitoring the effectiveness of therapy, were noted. The suboptimal efficacy of triple therapy is shown.
Published: 2019

23. DOP001 European Crohn's and Colitis Organisation topical review on environmental factors in IBD

Author: C. Maaser, E. Langholz, H. Gordon, J. Burisch, P. Ellul, V. Hernández, T. Karakan, K.H. Katsanos, E. Krustins, A. Levine, G.J. Mantzaris, C. O'Morain, E.S. Yuksel, H. Strid, and V. Annese
Subjects: Gastroenterology, General Medicine
Published: 2017

24. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study

Author: J, Molina-Infante, A J, Lucendo, T, Angueira, M, Rodriguez-Tellez, A, Perez-Aisa, A, Balboa, J, Barrio, E, Martin-Noguerol, B J, Gomez-Rodriguez, J M, Botargues-Bote, J, Gomez-Camarero, A, Huerta, I, Modolell, I, Ariño, M T, Herranz-Bachiller, F, Bermejo, A G, McNicholl, C, O'Morain, J P, Gisbert, and S, Prados
Subjects: Adult, Male, medicine.medical_specialty, Adolescent, Gastroenterology, Esomeprazole, Helicobacter Infections, Medication Adherence, Young Adult, Pharmacotherapy, Internal medicine, Clarithromycin, Metronidazole, Concomitant Therapy, medicine, Humans, Pharmacology (medical), Prospective Studies, Prospective cohort study, Adverse effect, Aged, Aged, 80 and over, Hepatology, biology, Helicobacter pylori, business.industry, Amoxicillin, Middle Aged, biology.organism_classification, Surgery, Anti-Bacterial Agents, Concomitant, Drug Therapy, Combination, Female, business, medicine.drug
Abstract: SummaryBackground Empiric triple therapy for Helicobacter pylori should be abandoned when clarithromycin resistance rate is >15–20%. Optimisation of triple therapy (high-dose acid suppression and 14-day duration) can increase eradication rates by 10%. Aim To compare the efficacy and safety of optimised triple (OPT-TRI) and nonbismuth quadruple concomitant (OPT-CON) therapies. Methods Prospective multicentre study in 16 Spanish centres using triple therapy in clinical practice. In a 3-month two-phase fashion, the first 402 patients received an OPT-TRI therapy [esomeprazole (40 mg b.d.), amoxicillin (1 g b.d) and clarithromycin (500 mg b.d) for 14 days] and the last 375 patients an OPT-CON treatment [OPT-TRI therapy plus metronidazole (500 mg b.d)]. Results Seven-hundred seventy-seven consecutive patients were included (402 OPT-TRI, 375 OPT-CON). The OPT-CON therapy achieved significantly higher eradication rates in the per-protocol [82.3% (95% CI = 78–86%) vs. 93.8% (91–96%), P 90%) compared to OPT-TRI therapy. Addition of metronidazole to OPT-TRI therapy increased eradication rates by 10%, resulting in more mild adverse effects, but without impairing compliance with therapy.
Published: 2014

25. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

Author: Malfertheiner, F. Megraud, C. O’Morain, E. El Omar, D. Graham, R. Hunt, T. Rokkas, N. Vakil, E. J. Kuipers, The European Helicobacter Study Group (EHSG, BAZZOLI, FRANCO, Malfertheiner, F Megraud, C O’Morain, F Bazzoli, E El-Omar, D Graham, R Hunt, T Rokka, N Vakil, E J Kuiper, The European Helicobacter Study Group (EHSG, and Gastroenterology & Hepatology
Subjects: Adult, medicine.medical_specialty, Atrophic gastritis, medicine.drug_class, Urea breath test, Proton-pump inhibitor, GUIDELINES, Gastroenterology, Helicobacter Infections, Stomach Neoplasms, Clarithromycin, Internal medicine, Drug Resistance, Bacterial, medicine, Humans, Helicobacter, Dyspepsia, Stomach cancer, Child, Antibacterial agent, biology, medicine.diagnostic_test, Helicobacter pylori, business.industry, Lymphoma, B-Cell, Marginal Zone, medicine.disease, biology.organism_classification, digestive system diseases, Anti-Bacterial Agents, Immunology, Gastroesophageal Reflux, business, medicine.drug
Abstract: Background: Guidelines on the management of Helicobacter pylori , which cover indications for management and treatment strategies, were produced in 2000. Aims: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer. Results: Eradication of H pylori infection is recommended in ( a ) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; ( b ) patients with atrophic gastritis; ( c ) first degree relatives of patients with gastric cancer; ( d ) patients with unexplained iron deficiency anaemia; and ( e ) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a “test and treat” strategy if other causes are excluded. Eradication of H pylori infection ( a ) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and ( b ) may prevent peptic ulcer in patients who are naive users of non-steroidal anti-inflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility. Conclusion: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.
Published: 2006

26. Irish society of gastroenterology

Author: M. P. Curry, S. Norris, J. E. Hegarty, F. Smith, N. Nolan, L. Golden-Mason, C. O’Farrelly, K. M. Walsh, A. Fletcher, R. N. M. MacSween, A. J. Morris, A. Bohan, E. Ryan, A-M. Flanagan, P. Martinez-Dalmau, J. Crowe, J. Kelly, O. Traynor, J. Mathias, P. A. McCormick, G. McEntee, J. Hegarty, S. Barrett, J. C. O’Keane, A. A. Shah, M. Berry, B. Thjodleifsson, I. Bjarnason, H. Gudjohnsson, E. Oddson, D. J. Fitzgerald, E. Kay, A. Price, F. E. Murray, E. Carton, E. D. Mulligan, M. T. P. Caldwell, D. Rana, B. Ryan, N. Mahmud, N. Keeling, W. A. Tanner, F. B. V. Keane, G. McDonald, J. V. Reynolds, Z. Mahmood, O. Rathore, I. Ellis, P. Byrne, P. W. N. Keeling, I. Khan, K. McManus, V. Anikin, M. Mills, J. McGuigan, C. Taylor, D. C. Winter, G. C. O’Sullivan, B. J. Harvey, M. W. Bennett, J. O’Connell, J. K. Collins, F. Shanahan, P. Wieneke, C. O’Leary, M. Healy, T. O’Halloran, R. Barry, C. C. Cronin, P. O’Regan, H. O’Grady, D. Grant, K. Sheahan, J. M. P. Hyland, D. P. O’Donoghue, J. Murphy, G. Lee, M. Madden, P. Shanahan, G. O. Sullivan, H. Shima, R. Basisht, K. Ohshiro, P. Puri, J. Goh, P. MacMathuna, A. Baird, C. Godson, H. R. Brady, N. A. Petasis, V. V. Fokin, G. McCormack, K. Khosraviani, H. P. Weir, K. Williamson, P. Hamilton, R. J. Moorehead, J. Mcllmoyle, R. G. P. Watson, J. S. A. Collins, T. C. K. Tham, R. M. Doyle, C. Molony, D. Fitzpatrick, D. Coakley, J. B. Walsh, D. Kelleher, E. Devitt, C. Keane, C. Walsh, K. P. Murray, H. S. Kaufman, J. H. Shin, H. A. Pitt, S. D. Johnston, S. A. McMillan, C. J. Larkin, J. M. Sloan, J. E. S. Ardill, J. S. Collins, K. D. Buchanan, W. J. Curry, C. F. Johnston, W. Curry, C. Johnston, J. Sloan, J. Ardill, R. Irvine, L. Gibson, G. Creedon, M. Mabruk, M. Leader, T. O’Grady, M. Murphy, B. Harhen, A. Hickey, N. Gannon, C. O’Boyle, R. Byrne, M. Smith, F. Murray, M. F. Byrne, J. Quinlan, C. P. Delaney, R. Varadarajan, J. M. Hyland, P. M. MacEneaney, S. J. Skehan, M. Curry, R. G. Gibney, D. E. Malone, S. Kealy, J. Dodd, R. Murrary, D. P. Donoghue, D. Keating, Z. Hashim, J. Donnellan, Y. O’Connor, M. Kearns, F. M. Stevens, S. Sookhai, J. H. Wang, P. Neary, M. McCourt, D. O’Connell, H. P. Redmond, E. McAteer, W. J. Campbell, E. J. Mackle, C. Smyth, S. McKiernan, M. Lawlor, K. Pilkington, R. Hagan, S. Montague, M. Buckley, C. A. O. Morain, C. Connolly, S. Tierney, J. Gray, N. D. Lyons, P. V. Delaney, P. A. Grace, L. Nemeth, D. S. O’Briain, C. O’Toole, D. Roddy, M. Griffin, T. P. J. Hennessy, C. O’Keffe, D. O’Donoghue, E. Murphy, J. Reynolds, J. J. Nolan, M. McAndrew, G. Clarke, S. Stewart, A. Cockram, B. Coughlan, J. Sheehan, E. E. Lang, D. McNamara, H. Hamilton, S. Beattie, C. O’Morain, H. J. Windle, A. Heaney, W. S. Chan, R. M. S. Mitchell, L. Feighery, K. Quane, M. Molloy, C. Feighery, C. O. Farrelly, B. M. Egan, M. K. Barry, D. C. Grant, P. Barry, P. Casey, M. Laffoy, J. Tracey, T. Goode, A. Hopkins, A. W. Baird, M. Kingston, M. Blackwell, P. F. O’Regan, L. J. Maher, and M. M. Skelly
Subjects: medicine.medical_specialty, Irish, business.industry, Ophthalmology, language, Medicine, Library science, General Medicine, business, language.human_language
Published: 1998

27. Irish society of gastroenterology

Author: B. M. Ryan, S. McKiernan, P. W. N. Keeling, P. J. Byrne, R. Quill, K. McCallion, R. M. S. Mitchell, R. G. P. Watson, J. S. A. Collins, K. R. Gardiner, D. C. Winter, G. C. O’Sullivan, C. T. Taylor, N. F. Fanning, H. P. Redmond, D. P. O’Donoghue, A. W. Baird, B. J. Harvey, A. E. Brannigan, P. R. O’Connell, M. C. Regan, J. M. Fitzpatrick, R. W. G. Watson, H. Lemass, E. Ryan, P. MacMathuna, J. Crowe, J. C. O’Keane, J. Goh, A. Baird, L. Maher, C. Godson, H. R. Brady, N. A. Petasis, V. V. Fokin, M. K. Barry, D. C. Grant, K. Sheahan, J. M. P. Hyland, K. M. Sheehan, D. J. Fitzgerald, F. E. Murray, A. Heaney, K. B. Bamford, R. J. McFarland, T. C. K. Tham, D. McNamara, S. Franelli, H. Whelan, H. Hamilton, S. Beattie, C. O’Morain, E. G. Brennan, N. O’Hare, R. McDermott, N. I. McDougall, C. M. Gieeson, S. E. H. Russell, J. M. Sloan, D. Morrisey, L. Murphy, B. Kiely, G. Fitzgerald, C. Daly, G. O’Sullivan, F. Shanahan, J. K. Collins, P. Marteau, S. D. Johnston, C. Coates, C. Feighery, J. O’Keeffe, A. Whelan, S. Lynch, D. G. Weir, M. Abuzakouk, L. Barnes, N. O’Gorman, M. McKenna, R. Freaney, M. Young, S. Gaines, D. Brady, D. Drudy, C. O’Farrelly, A. Gilleece, L. Fenelon, J. McPartlin, A. M. Hopkins, A. Myers, P. Moynagh, J. M. Kirby, M. J. Allen, B. Best, H. Calvert, S. Kirk, S. T. D. McKelvey, R. J. Moorehead, J. C. Varghese, S. Sookhai, T. Walsh, H. Osborne, P. Broe, M. J. Lee, D. Moriarty, R. Coffey, E. Murphy, A. A. Shah, E. Murray, B. Thjodleifsson, I. Bjarnason, S. Montague, C. Forkin, G. C. O’Toole, C. M. Gallagher, P. Connell, O. Traynor, T. C. Ling, B. Johnston, M. F. Byrne, M. A. Farrell, C. A. Goulding, S. S. Albloushi, P. O’Connell, L. E. Graham, T. J. Robinson, T. Jabeen, B. Cannon, D. Jenkins, M. J. Whelton, S. Bohra, C. Keohane, M. Duggan, R. K. Siddheshwar, R. G. Wilson, P. J. Hainsworth, F. C. Campbell, S. B. Kelly, B. M. Egan, C. Simutowe, D. A. McNamara, N. Collins, T. N. Walsh, A. Mukherjee, M. Scott, C. Pohl, E. Duggan, M. Wasi, A. Sarkar, L. O. Donnell, P. W. Eustace, J. G. Johnston, R. Waldron, S. Barrett, G. Callagy, J. C. O. Keane, B. Coughlan, J. Sheehan, A. Hickey, A. Carr, M. R. Kell, M. Lynch, D. Ryan, P. Rajpal, W. O. Kirwan, C. J. Larkin, J. E. S. Ardill, K. D. Buchanan, P. L. Lim, M. Gibbons, E. J. Crawford, B. T. Johnston, C. Rodgers, S. Johnston, B. M. Crone, A. H. G. Love, L. Feighery, J. Jackson, M. M. I. Yassin, D. W. Harkin, A. A. B. Barros D’sa, T. G. Parks, M. P. Curry, J. E. Hegarty, L. Golden-Mason, E. Hannigan, and N. Parfrey
Subjects: medicine.medical_specialty, Pediatrics, Irish, business.industry, Family medicine, medicine, language, General Medicine, business, language.human_language
Published: 1998

28. Irish cardiac society

Author: C. Seifer, B. McNeill, M. O’Donnell, K. Daly, J. Kellett, H. M. McGee, A. J. Montogomery, D. O’Callaghan, J. H. Horgan, N. G. Mahon, M. Codd, J. Brennan, B. Egan, H. A. McCann, D. D. Sugrue, I. B. A. Menown, R. S. H. W. Patterson, S. R. McMechan, S. Hameed, A. A. J. Adgey, S. H. Baird, S. J. McBride, T. G. Trouton, C. Wilson, J. P. McRedmond, D. J. Fitzgerald, J. J. Crowley, J-F. Tanguay, R. M. Santos, R. S. Stack, P. Keelan, C. J. McKenna, R. AuBuchon, A. R. Camrud, D. R. Holmes, R. S. Schwartz, R. Wolff, W. D. Edwards, C. Hanratty, D. McAuley, I. Young, G. Murtagh, B. O’Keeffe, G. Richardson, M. Scott, E. W. Chew, N. A. Bailie, A. M. J. Graham, H. O’Kane, H. M. Kwon, L. Ellis, R. Virmani, L. Noelke, A. E. Wood, H. Javadpour, D. Veerasingham, D. O’Kane, J. D. Allen, T. Hennessy, P. Johnson, D. Hildick-Smith, E. Winter, L. Shapiro, A. Lerman, L. T. McGrath, P. Passmore, B. Silke, A. G. Nugent, C. McGurk, S. Maguire, G. D. Johnston, S. L. Lovell, G. McDowell, D. McEneany, M. S. Riley, D. P. Nicholls, D. Gilligan, D. Sargent, D. Dan, G. Elam, B. Rhee, D. Keane, L. Zhou, B. McGovern, H. Garan, J. Ruskin, J. C. O’Shea, H-C. Tan, J. P. Zidar, D. B. O’Keeffe, S. Graffin, D. Fitzsimmons, S. Brown, D. Duff, B. Denham, F. Woods, M. Neligan, P. Oslizlok, C. K. Connolly, M. H. D. Danton, M. Danton, D. J. Gladstone, B. Craig, H. C. Mulholland, F. Casey, S. Chaudhuri, J. Hinchion, R. H. S. W. Patterson, G. MacKenzie, M. T. Harbinson, L. M. Burgess, V. Moohan, D. J. McEneaney, O. C. Finnegan, L. Doherty, J. G. Riddell, R. Meleady, L. Daly, I. Graham, M. Quinn, B. Foley, J. Lee, N. Mulvihill, P. Crean, M. Walsh, C. O’Morain, C. Hynes, S. M. King, S. David, H. Newton, M. Maguire, F. Rafferty, P. A. Sullivan, D. Murphy, S. Gallagher, J. Allen, J. McC Anderson, J. Hoag, D. Eckberg, J. Galvin, P. Diamond, T. Neilan, E. Keelan, null H. A., C. McCarthy, V. P. Moohan, G. M. Ayers, M. Roberts, L. Burgess, C. Anderson, M. Khan, I. P. Clements, W. L. Miller, F. Turtle, H. Long, W. McNair, N. P. S. Campbell, T. P. Mathew, M. Smye, G. S. Nesbitt, I. S. Young, D. Mulcahy, I. M. Graham, D. Moore, D. Sugrue, M. B. Codd, P. Zimmerman, J. Winget, M. Capeless, T. A. McKelvey, M. I. A. Sarsam, and D. McEneaney
Subjects: Irish, business.industry, language, Medicine, Library science, General Medicine, business, language.human_language
Published: 1998

29. Helicobacter Pylori: The Cancer Link

Author: M Buckley, F O'Connor, and C O'Morain
Subjects: medicine.medical_specialty, biology, business.industry, Spirillaceae, Cancer, General Medicine, Helicobacter pylori, medicine.disease, biology.organism_classification, Helicobacter Infections, Gastroenterology, 030227 psychiatry, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Immunology, medicine, Adenocarcinoma, 030212 general & internal medicine, business
Published: 1996

30. Double-blind, Multicenter, Placebo-Controlled Evaluation Of Clarithromycin And Omeprazole For Helicobacter Pylori-Associated Duodenal Ulcer

Author: C O'Morain, A Rambow, E von Fritsch, A G Fraser, and A Dettmer
Subjects: Adult, Male, medicine.medical_specialty, Placebo, Gastroenterology, Helicobacter Infections, law.invention, Pharmacotherapy, Double-Blind Method, Randomized controlled trial, Recurrence, law, Clarithromycin, Internal medicine, Gastric mucosa, Humans, Medicine, Life Tables, Enzyme Inhibitors, Omeprazole, Aged, Helicobacter pylori, biology, business.industry, Proton Pump Inhibitors, General Medicine, Middle Aged, Anti-Ulcer Agents, bacterial infections and mycoses, biology.organism_classification, Anti-Bacterial Agents, Clinical trial, Treatment Outcome, Infectious Diseases, medicine.anatomical_structure, Gastric Mucosa, Duodenal Ulcer, Gastritis, Patient Compliance, Drug Therapy, Combination, Female, business, medicine.drug
Abstract: Background.Eradication of Helicobacter pylori leads to faster ulcer healing and a significant decrease in ulcer recurrence. Clarithromycin is the most effective monotherapy for eradicating H. pylori from the gastric mucosa, and omeprazole frequently is used for the treatment of duodenal ulcer disease, prompting the interest to investigate rigorously the combination of clarithromycin and omeprazole for eradicating H. pylori. Materials and Methods.The aim of this double-blind, randomized, multicenter (n=30), multinational (n=10) study was to compare clarithromycin and omeprazole with omeprazole monotherapy for the eradication of H. pylori from the gastric mucosa, endoscopic healing, and reduction of symptoms and ulcer recurrence in patients with active duodenal ulcer. Patients with active duodenal ulcer associated with H. pylori infection were randomized to receive omeprazole, 40 mg every morning for 14 days, with either clarithromycin, 500 mg, or placebo three times daily, which was followed by omeprazole, 20 mg every morning for 14 days. Patients underwent endoscopy before enrolling in the study, immediately after finishing treatment, and at 4- to 6-week and 6-month follow-up evaluations or at the recurrence of symptoms. Results.Two hundred and eight patients with active duodenal ulcer associated with confirmed H. pylori infection were randomized to treatment with either clarithromycin and omeprazole (n=102) or omeprazole and placebo (n=106). Four to six weeks after treatment was completed, H. pylori was eradicated in 74% (95% confidence interval, 63.0%–82.4%) of patients receiving clarithromycin and omeprazole, compared with 1% (0.0%–6.2%) of patients receiving omeprazole monotherapy (p < .001). Clarithromycin resistance developed in eight patients treated with clarithromycin and omeprazole and in none given omeprazole and placebo. Ulcers, which were healed following treatment in more than 95% of study patients, recurred by the 6-month follow-up visit in 10% (5%–19%) of dual therapy recipients, compared with 50% (39%–61%) of those who took omeprazole alone (p
Published: 1996

31. Impaired gut barrier function in malnourished patients

Author: J. V. Reynolds, C. O'Farrelly, C. Feighery, P. Murchan, N. Leonard, G. Fulton, C. O'Morain, F. B. V. Keane, and W. A. Tanner
Subjects: Surgery
Published: 1996

32. Irish Society of Gastroenterology

Author: M. Woods, L. J. D. O’Donnell, B. Battistini, T. Warner, J. Vane, M. G. Fartming, J. Yaqoob, J. J. Wu, L. A. Norris, M. I. Khan, P. W. N. Keeling, D. Maguire, G. O’Sullivan, B. Harvey, B. Curran, Y. Xin∘, E. W. Kay, M. Leader, K. Henry, O. Crosbie, S. Norris, P. Costello, C. O’Farrelly, J. Hegarty, B. Kennedy, M. Duggan, R. Plant, E. K. Kenny-Walsh, P. Cotter, M. J. Whelton, M. Maloney, N. Noonan, M. Buckley, H. Hamilton, S. Beattie, C. O’Morain, B. McNamara, J. Cuffe, R. A. Barry, D. A. Collins, G. C. O’Sullivan, J. K. Collins, F. Shanahan, M. M. Skelly, H. E. Mulcahy, A. Troy, T. Connell, C. Duggan, M. J. Duffyt, K. Sheahan, D. P. O’Donoghue, H. X. Xia, D. Hyde, M. G. O’Brien, E. F. Fitzgerald, G. Lee, A. J. Hussey, T. J. Boyle, B. Garrihy, O. P. Clinton, O. J. McAnena, G. O’Sulllvan, H. Corby, V. Donnelly, C. O’Herlihy, P. R. O’Connell, T. Deignan, J. Kelly, N. P. Breslin, C. MacDonnell, J. O’Keeffe, K. Mills, U. Srinivasan, R. Willoughby, C. Feighery, B. Twohig, K. Gaynor, P. F. O’Regan, S. Duggan, H. P. Redmond, J. McCarthy, D. Bouchier-Hayes, Q. Y. Ma, K. E. Williamson, B. J. Rowlands, A. Tobin, R. Pilkington, M. O’Donnell, E. O’Shea, A. Conroy, G. Kaminski, A. Walsh, I. J. Temperley, D. Kelleher, D. G. Weir, M. K. Barry, E. D. Mulligan, M. A. Stokes, M. G. O’Riordain, T. F. Gorey, K. F. McGeeney, J. M. Fitzpatrick, R. W. G. Watson, J. H. Wang, F. Campbell, D. Bennett, E. Kavanagh, P. O. Gorman, P. O’Regan, M. M. I. Yassin, M. McCaigue, T. G. Parks, A. A. B. Barros D’Sa, M. Lawlor, S. McElwaine, M. A. Heneghan, M. Kerins, J. Goulding, E. L. Egan, F. M. Stevens, C. F. McCarthy, M. Quirke, A. M. Eustace-Ryan, S. Qureshi, E. Aziz, A. Maree, S. Collins, T. Browne, S. Ahmed, B. O. Sullibhan, P. Smith, F. Walker, F. O’Connor, E. Sweeney, R. J. Farrell, M. Morrint, M. Goggins, and J. G. McNulty
Subjects: medicine.medical_specialty, Irish, business.industry, Ophthalmology, language, medicine, Library science, General Medicine, business, language.human_language
Published: 1995

33. Irish Society of Gastroenterology

Author: P. K. Neelamakam, E. Brazil, S. Attwood, O. Traynor, J. Yaqoob, M. I. Khan, D. O’Toole, N. Noonan, C. Carey, D. Kelleher, D. G. Weir, P. W. N. Keeling, D. Monahan, L. Cogan, R. Willoughby, J. Jackson, A. Whelan, C. Feighery, G. Z. Kaminski, A. Conroy, S. Dooley, N. A. Parfrey, P. McEneaney, C. O’Morain, J. P. McGrath, R. C. Stuart, J. Hill, P. J. Byrne, C. Timon, S. C. S. Chung, A. VanHasselt, T. P. J. Hennessy, D. Hamilton, D. Mulcahy, D. Walsh, C. Farrely, W. Tormey, J. Fielding, G. Watson, A. Cherukuri, M. Maloney, D. O. Toole, M. Corcoran, J. Coffey, F. Butt, D. McAvinchey, P. V. Delaney, G. J. Burke, S. Youngprapakorn, U. Srinivasan, N. Leonard, C. O’Farrelly, C. O. Morain, C. A. Whelan, E. Barry, C. Collins, P. Costello, C. O’Herlihy, D. P. O’Donoghue, C. Clabby, J. McCarthy, E. Kenny-Walsh, M. J. Whelton, M. Morrin, F. Khan, P. Delaney, J. O’Keeffe, K. Mills, M. A. Bennett, E. W. Kay, H. Mulcahy, M. Leader, D. T. Croke, X. G. Fan, I. Khan, S. Keating, C. Morrison, M. Buckley, F. M. O’Reilly, C. Darby, M. G. Courtney, G. M. Murphy, J. F. Fielding, C. J. O’Boyle, T. J. Boyle, K. Mulhall, M. J. Kerin, D. Courtney, D. S. Quill, H. F. Given, S. Kehoe, R. Quirke, R. B. Stephens, S. Norris, G. McEntee, J. Hegarty, C. Farrelly, D. Thottaparambil, R. Thomas, G. Houghton, S. Sachithanandan, A. Geoghegan, S. Doyle, C. McCaul, T. N. Walsh, R. Farrell, B. Gusau, M. S. O’Mahoney, S. AlBloushi, J. Sachithanandan, J. Walshe, M. Carmody, J. Donohoe, A. G. Shattock, N. Parfrey, S. Lynch, L. Madrigal, J. McEntee, R. Murphy, Z. Ahmed, M. Ryan, C. Montwill, A. Morgan, P. Smith, F. Walker, A. Murphy, M. Moloney, S. McGrath, E. Taraneweh, A. K. Bhatia, D. O’Keeffe, P. McCarthy, E. Rajan, S. Albloushi, B. O’ Farrell, A. Shattock, D. Kearney, J. Lee, F. Gleeson, B. McNamara, J. Cuffe, G. C. O’Sullivan, B. J. Harvey, B. Curran, E. Kay, L. Lawler, S. E. A. Attwood, G. Bourke, J. Hyland, W. A. Owens, C. M. Loughrey, J. A. McAleer, K. G. McManus, J. F. Dillon, F. C. Wong, T. C. N. Lo, K. H. Chan, J. N. Plevris, N. D. C. Finlayson, J. D. Miller, I. A. D. Bouchier, P. C. Hayes, S. V. Walsh, L. J. Egan, C. E. Connolly, F. M. Stevens, E. L. Egan, C. F. McCarthy, Q. Y. Ma, G. D. Magee, J. E. Ardill, K. D. Buchanan, B. J. Rowlands, P. McGettigan, R. Chan, B. O’ Shea, J. McManus, J. Feely, J. Donoghue, N. Fanning, J. Mathias, P. Gillen, W. A. Tanner, F. B. V. Keane, D. M. Campbell, V. Donnelly, D. O’Connell, M. Behan, P. R. O’Connell, C. S. Ko, K. Mealy, B. M. Gusau, M. Goggins, J. Yakoub, R. J. Farrell, and N. Mahmud
Subjects: medicine.medical_specialty, Irish, business.industry, Ophthalmology, medicine, language, Library science, General Medicine, business, language.human_language
Published: 1995

34. National scientific medical meeting 1995 abstracts

Author: S. Norris, C. Collins, J. Hegarty, C. O’Farrelly, J. Carton, L. Madrigal, D. P. O’Donoghue, H. Holloway, J. F. Fielding, W. Mullins, S. W. Hone, M. Donnelly, F. Powell, A. W. Blayney, E. A. Cahill, S. F. Daly, M. J. Turner, P. A. Sullivan, M. McLoughlin, M. M. Skelly, H. E. Mulcahy, T. Connell, C. Duggan, M. J. Duffy, A. Troy, K. Sheahan, A. Whelan, C. M. Herra, C. T. Keane, H. Johnson, B. Lee, E. Doherty, T. McDonnell, D. Mulherin, O. FitzGerald, B. Bresnihan, H. M. Hassett, A. Boyce, V. Greig, C. O’Herlihy, P. P. A. Smyth, E. F. Roche, I. McCormack, E. Tempany, M. J. Cullen, D. F. Smith, Y. McBrinn, B. Murray, R. Freaney, D. Keating, M. J. McKenna, J. A. O’Hare, H. Alam, Q. Raza, M. Geoghegan, S. Killalea, M. Hall, J. Feely, L. Kyne, B. O’Hara, M. Cullen, I. M. Rea, J. P. Donnelly, R. W. Stout, P. Lacey, M. J. Donnelly, J. McGrath, T. P. Hennessy, C. V. I. Timon, D. Hyde, H. X. Xia, M. Buckley, C. O’Morain, S. Keating, H. Xia, J. P. McGrath, R. C. Stuart, P. Lawlor, P. J. Byrne, T. N. Walsh, T. P. J. Hennessy, M. Duffy, M. Tubridy, J. Redmond, K. Monahan, R. P. Murphy, D. R. Headon, T. O’Gorman, F. M. O’Reilly, C. Darby, G. M. Murphy, A. Murphy, M. Codd, P. Dervan, D. Lawlor, S. O. Loughlin, N. Flanagan, R. Watson, L. Barnes, C. Kilgallen, E. Sweeney, A. Mynes, D. Mooney, I. Donoghue, O. Browne, J. A. Kirrane, D. McKenna, M. Young, E. O’Toole, S. O’Briain, U. Srinivasan, C. Feighery, N. Leonard, E. Jones, M. A. Moloney, D. G. Weir, M. Lawler, A. O’Neill, H. Gowing, D. Pamphilon, S. R. McCann, G. O’Toole, A. Orren, C. M. Seifer, D. C. Crowley, G. J. Sheehan, T. Deignan, J. Kelly, V. J. Tormey, J. Faul, C. Leonard, C. M. Burke, L. W. Poulter, S. Lynch, G. McEntee, O. Traynor, E. Barry, P. Costello, A. Keavney, R. Willoughby, C. O’Donnell, M. Cahill, A. Earley, P. Eustace, R. Osborne, C. Saidlear, B. Holmes, A. Early, A. P. Moran, A. Neisser, R. J. Polt, H. Bernheimer, M. Kainz, B. Schwerer, L. Gallagher, R. Firth, N. Kennedy, E. McGilloway, N. Tubridy, K. Shields, W. K. Cullen, M. J. Rowan, A. R. Moore, M. Rowan, D. Coakley, B. Lawlor, G. Swanwick, R. Al-Naeemi, R. Murphy, N. M. Codd, M. Goggins, N. P. Kennedy, B. L. Mallon, H. Mulcahy, M. Skelly, D. O. Donoghue, D. McCarthy, A. Saunders, D. J. Veale, J. J. F. Belch, D. Breathnach, E. Murphy, G. Kernohan, K. Gibson, A. G. Wilson, G. W. Duff, N. de Vries, L. B. A. van de Putte, J. Donoghue, F. O’Kelly, Z. Johnson, T. Maher, A. Moran, C. Keane, D. O’Neill, N. Horgan, J. M. Barragry, D. M. Campbell, M. Behan, P. R. O’Connell, V. S. Donnelly, D. Crowley, M. Geary, P. Boylan, M. Fanagan, K. Hickey, T. Teoh, M. Doyle, R. Harrison, D. Lyons, Y. Shenouda, M. Coughlan, P. McKenna, P. Lenehan, M. Foley, P. Kelehan, P. Ravichandran, M. Kelly, A. Conroy, C. Fitzpatrick, D. Egan, C. L. Regan, B. V. McAdam, P. McParland, G. A. FitzGerald, D. J. Fitzgerald, S. C. Sharma, K. Foran, C. Barry-Kinsella, R. F. Harrison, F. J. Gillespie, P. O’Mahony, M. Boyle, M. J. White, F. Donohoe, Y. Birrane, M. Naughton, R. B. Fitzsimons, M. Piracha, S. McConkey, E. Griffin, E. Hayes, T. Clarke, N. Parfrey, K. Butler, A. J. Malone, P. J. Kearney, P. F. Duggan, A. Lane, R. Keville, M. Turner, S. Barry, D. Sloan, S. Gallagher, M. Darby, P. Galligan, J. Stack, N. Walsh, M. O’Sullivan, M. Fitzgerald, D. Meagher, S. Browne, C. Larkin, P. Casey, E. O’Callaghan, S. Rooney, E. Walsh, M. Morris, T. Burke, M. Roe, C. Maher, M. Wrigley, M. Gill, M. Burgess, E. Corcoran, D. Walsh, B. Gilmer, C. B. Hayes, L. Thornton, J. Fogarty, R. Lyons, M. O’Connor, V. Delaney, K. Buckley, D. Lillis, V. Delany, C. Hayes, P. Dack, D. Igoe, H. J. O’Neill, P. Kelly, D. McKeown, L. Clancy, G. Varghese, S. Hennessy, J. J. Gilmartin, K. Birthistle, D. Carrington, H. Maguire, P. Atkinson, C. Foley-Nolan, M. Lynch, B. Cryan, D. Whyte, C. Conlon, V. Kucinskas, U. Usinskiene, I. Sakalyte, E. Dawson, K. Molloy, N. Goulden, J. Doyle, E. Lawlor, M. G. Harrington, N. El-Nageh, M. -L. Nolan, J. O’Riordan, G. Judge, G. Crotty, T. Finch, M. Borton, T. Barnes, O. Gilligan, G. Lee, R. Limmer, M. Madden, C. Bergin, A. O’Leary, F. Mulcahy, F. Wallis, M. Glennon, M. Cormican, U. NiRiain, M. Heiginbothom, F. Gannon, T. Smith, C. O’Sullivan, R. Hone, D. A. Caugant, C. A. P. Fijen, E. J. Van Schalkwyk, G. J. Coetzee, U. Ni Riain, M. G. Cormican, L. Park, J. Flynn, V. Regazzoli, M. Hayes, G. Nicholson, P. Higgins, N. Flynn, G. Corbett-Feeney, D. J. Conway, N. J. O’Higgins, S. Rajendiran, J. Byrne, E. Kilfeather, P. Dingle, M. Hunter, S. K. Al-Ghazal, P. Stanley, J. Palmer, A. Hong, P. Saxby, D. Sheehan, I. Regan, J. O’Mullane, M. Ni Chaoimh, M. Leahy, J. J. Heffron, M. Lehane, C. Keohane, N. O’Leary, M. Sheehan, E. Renny-Walsh, M. J. Whelton, C. T. Doyle, J. Webster, N. Benjamin, S. FitzGerald, J. S. Chadha, M. G. FitzGerald, G. R. FitzGerald, L. Hemeryck, P. McGettigan, J. Golden, N. Arthur, S. Y. Wen, P. Deegan, T. Cooke, G. I. Adebayo, P. Gaffney, M. Sinnot, D. O’Riordan, T. Hayes, C. M. O’Connor, M. X. FitzGerald, C. Costello, G. Finlay, J. Hayes, C. O’Connor, K. McMahon, S. Hone, J. Robertson, R. Coakley, S. O’Neill, M. Walsh, J. McCarthy, D. Lannon, A. E. Wood, R. Sharkey, E. Mulloy, M. Long, I. Kilgallen, V. Tormey, S. Horne, T. Feeney, Ó. Ó Muiré, M. J. Griffin, D. Hughes, A. Knaggs, D. Magee, C. McCrory, B. March, D. Phelan, M. White, J. Fabry, D. Buggy, C. Cooney, E. Aziz, D. O’Keefe, A. J. McShane, J. Boylan, E. Tobin, C. Motherway, F. Colreavy, N. Denish, R. Dwyer, A. Bergin, K. O’Brien, R. MacSullivan, K. D. Carson, W. P. Blunnie, D. C. Moriarty, B. Kinirons, B. Lyons, N. Cregg, W. Casey, K. P. Moore, S. A. Colbert, C. Ecoffey, D. O’Gorman, J. Fitzgerald, P. Diamond, M. B. Codd, D. D. Sugrue, J. Kellett, M. Tighe, C. J. McKenna, J. Galvin, H. A. McCann, A. Scallon, A. Fraser, M. Norton, G. Tomkin, I. Graham, A. Byrne, M. Maher, N. Moran, D. Fitzgerald, D. O’Callaghan, D. Coyle, A. G. Nugent, C. McGurk, G. D. Johnston, A. Nugent, B. Silke, N. Murphy, L. Jennings, D. Pratico, C. Doyle, T. Hennessy, H. McCann, D. Sugrue, S. Donnelly, A. Hennessy, C. Hartigan, D. MacDonald, S. Blake, D. McDonald, D. Dominque, S. R. McMechan, G. MacKenzie, J. Allen, G. T. Wright, G. J. Dempsey, M. Crawley, J. Anderson, A. A. J. Adgey, M. T. Harbinson, N. P. S. Campbell, C. M. Wilson, P. K. Ellis, E. M. McIlrath, A. McShane, T. V. Keaveny, K. Rabenstein, F. Scheller, D. Pfeiffer, C. Urban, I. Moser, G. Jobst, A. Manz, S. Verpoorte, F. Dempsey, D. Diamond, M. Smyth, E. Dempsey, V. Hamilton, J. Twomey, R. Crowley, L. Fenelon, F. Walsh, J. McCann, P. McDonagh, E. McGovern, D. Luke, K. Crowley, D. Mannion, D. Murphy, K. Clarkson, E. Carton, I. Leonard, D. O’Toole, M. Staunton, M. Griffin, D. Owens, P. Collins, A. Johnson, G. H. Tomkin, N. A. Herity, J. D. Allen, R. O’Moore, G. M. Crotty, M. DeArce, K. Nikookam, P. Keenan, D. Cregan, N. O’Meara, S. Forman, D. A. Cusack, and B. Farrell
Subjects: medicine.medical_specialty, business.industry, Family medicine, medicine, MEDLINE, General Medicine, business
Published: 1995

35. Irish Society of Gastroenterology

Author: D. F. Smith, N. Leonard, Michael J. Kerin, Brian J. Harvey, M. Duggan, Jiang Huai Wang, S. McDonald, J. S. A. Collins, Malachi J. McKenna, Frank B. V. Keane, Cormac T. Taylor, E. Mulligan, C. Kelly, N. Fanning, M. G. Goggins, David Bouchier-Hayes, W. A. Tanner, T. Hogan, F. Barker, S. Keating, B. T. Johnston, W. R.F. Ferguson, G. Thornton, Oliver J. McAnena, Colm O'Morain, G. P. McEntee, U. Srinivasan, K. B. Bamford, Alan W. Baird, Éanna J Ryan, O. Crosbie, A. Whelan, J. Crowe, Simon Keely, Terry Boyle, A. Pryde, J. Carton, Derek Moriarty, F. O’Brien, Niall Breslin, M. O’Riordain, S. Montague C. O'Morain, B. Crowley, N. McCallion, K. Synnott, D. P. O'Donoghoe, N. A. Parfrey, P. McEneaney, P. MacMathuna, Claire Condron, M. K. Barry, D. P. O’Donoghue, S. Doyle, T. P. J. Hennessy, Henry Paul Redmond, S. Beattie, J. M. Sloan, T. N. Walsh, J. K. Collins, M. Casey, R. B. Mooney, O. P. Clinton, M. A. Stokes, Cliona O'Farrelly, John M. Fitzpatrick, Dermot Kelleher, K. F. McGeeney, S. Duggan, I. Frazer, C. Feighery, H. Hamilton, A. G. Shattock, C. McCormick, Diarmuid O'Donoghue, P. McGurgan, G. O'Sullivan, K. C. Trimble, X. J. Fan, Thomas F. Gorey, P. R. O'Connell, D. Carroll, N. Mahmud, Margaret O'Mahony, G. Kelly, N. I. McDougall, T. C. K. Tham, L. Madrigal, Javed Yakoob, Peter J. Kelly, S. Douglas, R. C. Heading, J. Quinn, Gerald C. O'Sullivan, P. Lawlor, J. P. O'Donoghue, D. Maguire, Andrew H.G. Love, D. Booth, D. J. Reen, M. M. Skelly, D. Graham, E. M. Murray, Paul G. Horgan, F. Campbell, J. F. Fielding, X. G. Fan, K. Mealy, Donald G. Weir, R. Merriman, A. Long, R. C. Stuart, A. Keaveny, M. G. O'Sullivan, A. E. Brannigan, J. M. O≿donoghue, C. Morrison, A. Conroy, R. J. McFarland, S. Sachithanandan, Rosemarie Freaney, J. Lennon, Patrick J. Byrne, S. Al-Bloushi, P. Gillen, J. P. McGrath, G. S. A. McDonald, A. Weerkamp, R. G. P. Watson, C. Scanlon, P. W. N. Keeling, J. Hegarty, Maria M. Buckley, J. Mathias, M. C. Regan, Fergus Shanahan, R. W. G. Watson, K. Barry, M. G. Courtney, and Suzanne Norris
Subjects: medicine.medical_specialty, Irish, business.industry, Ophthalmology, language, Medicine, Library science, General Medicine, business, language.human_language
Published: 1994

36. Ulcerative Colitis and Pregnancy

Author: C. O’Morain and A. Alakkari
Subjects: Pediatrics, medicine.medical_specialty, Modern medicine, Pregnancy, education.field_of_study, business.industry, media_common.quotation_subject, Population, Fertility, Disease, medicine.disease, Low birth weight, Maintenance therapy, medicine, medicine.symptom, business, education, Breast feeding, media_common
Abstract: Ulcerative Colitis (UC) is a chronic inflammatory condition that frequently affects men and women of childbearing age. Concerns are often raised by both patients and clinicians regarding the effects of the disease and its treatments on reproduction and lactation. Many studies have examined fertility in UC patients in comparison with the general population. Most of these have not demonstrated a significant difference between the two groups. The observed decrease in fertility in some reports was largely attributable to patient choice, and the use of certain drugs such as sulfasalazine in men. Decreased fertility was also reported in women who have undergone surgery for their disease. Pregnancy is considered high risk in patients with UC. Numerous studies have described the obstetric and neonatal outcomes of these patients, and reported similar pregnancy outcomes in comparison to the general population. However some population-based studies have found an increased incidence of low birth weight and preterm delivery in UC patients. This observed difference seems to be mainly related to disease activity and severity during pregnancy and the appropriate treatment required. On the other hand pregnancy does not appear to increase the risk of disease relapse or severity. The course of UC during pregnancy is partly determined by its activity at conception. Therefore UC patients should be advised to attempt to conceive during periods of disease remission. Patients are often concerned about the safety of UC pharmacotherapy during pregnancy and lactation. Some patients choose to discontinue their maintenance therapy at least until the birth of their baby while others rely on their treating clinician to make the appropriate and safe decision regarding their treatment. Two issues have to be considered in this setting; first is the relative safety of the drug and secondly the benefit risk ratio of its use in pregnancy and lactation. A large amount of safety data is available on drugs that have been in use for decades, however modern medicine has witnessed the introduction of new therapeutic agents that have revolutionized the treatment of inflammatory diseases but there is limited data available regarding their safety during pregnancy and breast feeding. The topic of UC and pregnancy is quite complex involving a range of issues including the effects of both the disease and its treatment options on fertility, pregnancy and lactation, in addition to the effects of pregnancy and lactation on the course of the disease. The aim of this chapter is to review the available data and discuss this topic in more detail.
Published: 2011

37. Review article: defining remission in ulcerative colitis

Author: S P L, Travis, P D R, Higgins, T, Orchard, C J, Van Der Woude, R, Panaccione, A, Bitton, C, O'Morain, J, Panés, A, Sturm, W, Reinisch, M A, Kamm, and G, D'Haens
Subjects: Clinical Trials as Topic, Treatment Outcome, Gastrointestinal Agents, Practice Guidelines as Topic, Remission Induction, Humans, Colitis, Ulcerative, Endoscopy, Gastrointestinal
Abstract: There is no international agreement on scoring systems used to measure disease activity in ulcerative colitis, nor is there a validated definition for disease remission.To review the principles and components for defining remission in ulcerative colitis and propose a definition that will help improve patient outcomes.A review of current standards of remission from the perspective of clinical trials, guidelines, clinical practice and patients was conducted by the authors. Selected literature focused on the components of a definition of remission, the utility of a definition and treatment strategies, based on current definitions.Different definitions of remission affect the assessment of outcome and make it difficult to compare trials. In the clinic, endoscopy is rarely used to confirm remission, because mucosal healing has only recently begun to be related to the duration of subsequent remission in a way that will affect clinical practice. Histopathology may be the ultimate arbiter of mucosal healing. There is no agreement on the definition of remission in current guidelines. Patient-defined remission may predict endoscopic remission, but has yet to be shown to predict duration of remission.A standard based on clinical symptoms and endoscopy is proposed. Histopathology is a third dimension of remission that may have prognostic value. The definition of remission should help predict long-term outcome. The expectations of patients and their physicians need to be raised, as the goal of treatment of active ulcerative colitis should be to induce remission.
Published: 2011

38. Large-diameter plasma profile monitoring system using Faraday cup and Langmuir probe arrays

Author: C O'Morain, S Den, Y Hayashi, and Patrick O'Keeffe
Subjects: Materials science, business.industry, Plasma parameters, Applied Mathematics, Faraday cup, Ion current, Plasma, Electron cyclotron resonance, symbols.namesake, Optics, Nuclear magnetic resonance, Physics::Plasma Physics, Personal computer, symbols, Langmuir probe, Plasma diagnostics, business, Instrumentation, Engineering (miscellaneous)
Abstract: Details of a personal computer-based data acquisition system, which allows monitoring of large-diameter plasma source ion current profiles and Langmuir probe data, using an interchangeable rotatable, Faraday cup array and Langmuir probe array respectively are described. The arrays span the plasma diameter and can be rotated under computer control. Software-selectable monitor modes allow investigation of the angular and temporal dependence of ion current profiles, basic plasma parameters and their associated non-uniformities. Isolated aluminium plates can be fixed to the respective arrays to investigate the intrusive influence of a substrate holder and substrate bias on plasma parameters. Angular dependences is of ion current non-uniformity values of a large-diameter permanent magnet electron cyclotron resonance source are reported to demonstrate the benefits of the system over a single-probe/cup system.
Published: 1993

39. Irish association of rheumatology & rehabilitation

Author: J. J. Cushnaghan, M. Farahat, M. McCabe, J. O’Byrne, R. Ehman, D. J. Reen, A. E. Irvine, M. Martin, Y. Hough, E. B. Casey, D. Feighery, F. McConneir, H. Dyson, U. Srinivasan, J. Ryan, M. Abuzakouk, S. Lau, J. Stack, J. T. Lie, A. L. Bell, F. Kirk, N. Hall, A. Campbell, C. Feighery, P. W. N. Keeling, D. Legge, A. Garrahy, D. Foley-Nolan, C. O. Farrelly, F. O’Gara, K. M. Magill, B. Bresnihan, G. S. Panayi, J. D. O’Duffy, M. Kearney, T. Smith, J. Cushnaghan, E. Wallace, H. Monaghan, A. M. Forde, A. Arora, D. A. Isenberg, J. Williams, R. J. Coughlan, M. McDermott, S. Stanhope, J. Hunt, C. McCarthy, M. M. Stephens, E. M. O. Nuallain, M. Sitiny, D. Veal, D. Weir, T. A. McNeill, M. P. Lynch, R. Posten, F. M. Mulcahy, H. Winska-Wiloch, J. McCarthy, G. H. Kingsley, S. Sant, J. R. McKane, R. B. Sim, S. J. McBride, C. Williams, J. M. Thompson, D. Brophy, P. A. Dieppe, D. Rowbotham, A. Murphy, M. G. Molloy, P. Dieppe, O. Beausang, M. X. Fitzgerald, F. Camilleri, A. Chua, J. Bonnar, A. O’Mally, A. G. Engel, C. O’Farrelly, M. McLaren, D. N. Golding, J. Byrne, J. D. Edgar, P. Cashin, K. Lohmann Siegel, S. Griffin, D. Mulcahy, J. Hassan, J. J. F. Belch, M. Lynch, G. Cunnane, M. Heffernan, G. Yanni, L. H. Gerber, P. Plunkett, M. J. I. Phelan, P. G. O’Connell, A. J. Bancroft, A. Whelan, Oliver FitzGerald, R. Cahill, H. Hamilton, A. Long, R. Bucknall, E. Ghadiali, A. D. Crockard, Dermot Kelleher, S. Donnelly, S. Beattie, J. Gilvarry, M. Harrison, R. Gibney, D. Mulherin, E. Choy, S. Eustace, C. O’Morain, E. Casey, E. Breathnach, B. Coughlan, and J. Jackson
Subjects: medicine.medical_specialty, Rehabilitation, business.industry, medicine.medical_treatment, General Medicine, language.human_language, Rheumatology, Irish, Family medicine, Internal medicine, medicine, language, Optometry, business
Published: 1993

40. Irish Society of Gastroenterology

Author: J. Coleman, D. Bouchier Hayes, M. A. Daw, R. O’More, C. T. Keane, C. O’Morain, G. W. Johnson, E. F. A. Spencer, A. J. Wilkinson, T. L. Kennedy, J. S. A. Collins, K. B. Bamford, B. J. Collins, J. M. Sloan, R. J. Moorehead, A. H. G. Love, C. McCarthy, R. Collins, S. Beattie, J. McDevitt, C. Feighery, C. O’Farrelly, D. G. Weir, D. Kelleher, A. Whelan, Y. Williams, D. Kellegher, D. Weir, M. C. Prabhakar, M. Daw, F. Keane, E. W. M. McDermott, B. Duduric, M. F. Brennan, R. Gaffney, J. O’Leary, T. Doyle, A. Gaffney, D. B. Gough, K. C. H. Fearon, P. Winstanley, D. C. Carter, O. J. McAnena, F. A. Moore, E. E. Moore, R. Pogetti, V. M. Peterson, C. M. Abemathy, P. Parsons, N. N. Williams, J. M. Daly, M. Herlyn, D. Bouchier-Hayes, N. F. Course, P. G. Horgan, A. Fahy, C. Delaney, J. M. Fitzpatrick, T. F. Gorey, S. Jazrawl, T. N. Walsh, P. J. Byrne, P. Lawlor, T. P. J. Hennessy, K. R. O’Sullivan, P. M. Mathias, M. McNicholas, M. Logan, J. Masterson, P. Gillen, J. Hyland, E. Beausang, W. P. Joyce, N. Williams, W. Maxwell, I. Reid, I. Sharpe, J. G. Geraghty, W. A. Tanner, S. Patchett, H. Mulcahy, N. Afdhal, D. O’Donoghue, A. Lohan, A. Darzi, F. B. V. Keane, P. W. N. Keeling, R. C. Gibney, R. Keane, J. Drumm, T. J. Egan, P. V. Delaney, G. O’Sullivan, P. Harte, P. A. Grace, A. Qureshi, H. Osbome, D. J. Bouchier-Hayes, S. L. Bamford, J. Geraghty, F. B. Keane, J. E. Coleman, A. Gleeson, K. Mealy, M. Barry, O. Traynor, J. J. Keating, A. Chua, S. Ah-Kion, J. McNulty, L. G. Heaney, P. Murphy, J. H. Connolly, M. E. Callender, P. MacMathuna, M. Farrant, D. O. B. Hourihane, P. Donaldson, M. Lombard, D. Westaby, Roger Williams, N. F. Couse, J. Burke, G. Lennon, C. P. Delaneyc, S. O’Brien, A. O’Brien, M. X. Fitzgerald, J. E. Hegarty, N. Noonan, M. Healy, R. O’Moore, O. I. Corrigan, P. W. N. Keating, H. U. I. Li, R. C. Stuart, S. Jazrawi, D. Wai, H. Jaeger, A. M. Jackson, C. J. Mitchell, J. MacFie, C. P. Delaney, K. McGeeney, M. T. P. Caldwell, D. P. O’Donoghue, J. Connolly, E. Kay, T. Gorey, P. McKiernan, J. F. T. Glasgow, B. T. Johnson, R. Ferguson, I. Davidson, J. Hurley, P. Keeling, T. Crowley, A. A. Long, D. P. O’Brien, R. P. Waldron, M. J. Shearer, H. F. Given, G. McEntee, J. Monson, J. Donohue, D. Nagomey, K. C. Trimble, A. M. Molloy, J. M. Scott, J. McKeever, and T. P. J. Hennessey
Subjects: Irish, business.industry, language, Medicine, Library science, General Medicine, business, language.human_language
Published: 1993

41. Ornithine decarboxylase G316A genotype and colorectal cancer risk

Author: D J, Hughes, I, Hlavatá, P, Soucek, B, Pardini, A, Naccarati, L, Vodickova, C, O'Morain, and P, Vodicka
Subjects: Adult, Aged, 80 and over, Male, Genotype, Rectal Neoplasms, Carcinoma, Middle Aged, Ornithine Decarboxylase, Polymorphism, Single Nucleotide, Introns, Logistic Models, Case-Control Studies, Colonic Neoplasms, Humans, Female, Aged, Czech Republic
Abstract: Ornithine decarboxylase (ODC) is a modifier of adenomatous polyposis coli-dependent tumourigenesis. The G316A polymorphism in intron 1 of the ODC gene lies between two myc-binding domains and alters the expression of the gene to affect polyamine metabolism. This variant may be associated with recurrence of colorectal adenoma. We examined whether this variant also modified the susceptibility to sporadic colorectal cancer (CRC).The G316A variant was analysed in a large (n = 754) CRC case-controlled series of hospital patient volunteers (n = 627) in the Czech Republic, and the relationship with cancer risk was estimated by conditional logistic regression.After adjusting for age and sex, G316A was associated with no decrease in CRC risk for either heterozygotes [odds ratio 0.98, 95% confidence interval (CI) 0.77-1.23] or rare allele homozygotes (odds ratio 0.92, 95% CI 0.61-1.37).The G316A functional variant in the ODC gene is unlikely to make much impact on reducing CRC risk regardless of the reduction in risk found for the recurrence of colorectal adenoma.
Published: 2010

42. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis

Author: S, Odes, H, Vardi, M, Friger, D, Esser, F, Wolters, B, Moum, H, Waters, M, Elkjaer, T, Bernklev, E, Tsianos, C, O'Morain, R, Stockbrügger, P, Munkholm, and E, Langholz
Subjects: Adult, Male, Middle Aged, Markov Chains, Europe, Young Adult, Treatment Outcome, Crohn Disease, Adrenal Cortex Hormones, Population Surveillance, Humans, Colitis, Ulcerative, Female, Israel, Digestive System Surgical Procedures, Immunosuppressive Agents
Abstract: Forecasting clinical and economic outcomes in ulcerative colitis (UC) and Crohn's disease (CD) patients is complex, but necessary.To determine: the frequency of treatment-classified clinical states; the probability of transition between states; and the economic outcomes.Newly diagnosed UC and CD patients, allocated into seven clinical states by medical and surgical treatments recorded in serial 3-month cycles, underwent Markov analysis.Over 10 years, 630 UC and 318 CD patients had 22,823 and 11,871 cycles. The most frequent clinical outcomes were medical/surgical remission (medication-free) and mild disease (on 5-aminosalicylates, antibiotics, topical corticosteroids), comprising 28% and 62% of UC cycles and 24% and 51% of CD cycles respectively. The probability of drug-response in patients receiving systemic corticosteroids/immunomodulators was 0.74 in UC, 0.66 in CD. Both diseases had similar likelihood of persistent drug-dependency or drug-refractoriness. Surgery was more probable in CD, 0.20, than UC, 0.08. In terms of economic outcomes, surgery was costlier in UC per cycle, but the outlay over 10 years was greater in CD. Drug-refractory UC and CD cases engendered high costs in the cohort.Most patients on 5-aminosalicylates, corticosteroids and immunomodulators had favourable clinical and economic outcomes over 10 years. Drug-refractory and surgical patients exhibited greater long-term expenses.
Published: 2010

43. Treatment

Author: C. S. Goodwin, B. Worsley, E. Pillai, V. Willems, H. D. Janisch, H. Langmaack, P. Sanchez, M. Alcalde, A. Lancho, P. Carpintero, R. Garcia, J. M. Pajares, P. Ya. Grigoriev, V. A. Isakov, E. P. Iakovenko, A. V. Iakovenko, K. Vogt, H. Hahn, I. H. Rehmann, M. Hedding-Eckerich, J. Blessing, G. M. Sobala, D. A. F. Lynch, B. Gallacher, M. F. Dixon, A. T. R. Axon, E. Bayerdörffer, G. Mannes, A. Sommer, W. Höchter, J. Weingart, R. Hatz, S. Miehlke, N. Lehn, G. Ruckdeschel, P. Dirschedl, M. Stolte, R. J. Adamek, M. Wegener, S. Birkholz, W. Opferkuch, G. H. Rühl, B. Wedmann, J. Labenz, E. Gyenes, G. H. R’hl, G. Börsch, R. Maieron, C. Rizzi, L. Zoratti, S. Andreoli, G. L. Da Broi, C. A. Beltrami, Zhuya Chengyl, Mou Yangiong, Hua Jiesong, Zhang Zhenhua, L. Bierti, E. G. Bolis, R. Di Battista, R. de Franchis, D. J. McAvinchey, M. Laurence, J. O’Riordan, M. Fantazi, M. Khawaja, E Bologna, M. Stroppiana, S. Peyre, R. Pulitano’, C. Sategna-Guidetti, E. Martin, T. Alarcön, J. C. Sanz, M. I. Jimonez, M. López-Brea, A. Burette, Y. Glupczynski, C. Deprez, F. Di Mario, M. Ferrana, G. Battaglia, P. Dotto, F. Vianello, G. A. Grasso, R. Fiocca, L. Villiani, O. Luinetti, A. Gianatti, R. Boldorini, M. Lazzaroni, G. Bianchi Porro, E. Trespi, M. Perego, C. Alvisi, B. Cesana, E. Solcia, R. P. H. Logan, R. R. Greaves, P. A. Gummett, M. M. Walker, Q. N. Karim, A. E. Duggan, J. H. Baron, J. J. Misiewicz, J. Lohmarm, L. H. H. Porst, J. Schönlebe, H. Riedel, F. Catalano, G. Rizzo, M. T. Ayoubi Khajekini, G. Branciforte, G. Inserra, A. Liberti, R. Suriani, C. Pallante, M. Ravizza, D. Mazzucco, D. Galliano, M. Malandrino, R. Oneglio, M. Colozza, E. Gaia, F. Sallio, D. Colozza, C. Grandis, G. B. Forte, M. E. Bottiglieri, R. Durasco, E. Grimaldi, P. Rocco, H. X. Xia, M. A. Daw, S. Sant, S. Beattie, C. T. Keane, C. A. O’Morain, H. Larsson, M. L. Berglund, P. Tessaro, R. Schiavon, M. G. Contini, T. Ton, L. Norberto, M. Cassaro, M. Rugge, M. Guido, R. Baffa, S. Gloriosa, F. Turatello, R. Naccarato, R. Collins, C. O’Moram, T. P. Kemmer, J. E. Dominguez-Munoz, H. Klingel, P. Malfertheiner, C. J. McCarthy, M. McDermott, D. Hourihane, C. O’Morain, M. T. Droy-Lefiax, B. Forestier, D. Guillomain, O. Plique, D. Brugmann, F. Mégraud, H. Lamouliatte, P. H. Bernard, R. Cayla, M. Mégraud, A. de Mascarel, A. Quintonl, A. McLaren, S. R. McDowell, A. A. McColm, C. O’Malley, J. Bagshaw, F. Bouffant, P. Marelli, L. Cellini, M. Campa, B. Dainelli, G. Soldani, M. del Tacca, G. Ferrini, G. Larcinese, N. Semperlotti, Gy. Molnar, A. Fzentmihalyi, A. Takats, G. Gero, J. Penyige, Gy. Mark, J. Martínez-Gómez, D. García-Novo, D. Acuña-Quinõs, M. Gimeno, S. Vigneri, R. Termini, A. Scialabba, G. Pisciotta, R. Gusmaroli, F. Milesi, P. Mule, M. Menegatti, C. Reale, J. Holten, and D. Vaira
Subjects: General Medicine
Published: 1992

44. Microbiology

Author: N. Figura, R. J. Owen, M. Desai, P. F. Bayeli, L. Di HGregorio, M. Russi, R. A. Musmanno, P. R. Hawtin, D. Sharpstone, L. Hayes, A. Nøorgaard, H. Nielsen, L. P. Andersen, G. Geis, H. Leying, S. Suerbaum, W. Opferkuch, Y. Tonokatsu, T. Hayashi, Y. Fukuda, I. Yamamoto, S. Takami, T. Tamura, T. Shimoyama, M. Lopez-Brea, E. Martin, J. C.Sanz, M. Alonso, T. Alarcon, P. Michetti, N. Porta, L. Racine, J. P.Kraehenbuhl, A. L.Blum, L. Cardeñoso, A. P. Moran, A. Muotiala, L. Pyhälä, T. U. Kosunen, I. M. Helander, R. P. Roine, K. S. Salmela, J. Höök-Nikanne, M. Salaspuro, M. A. Daw, H. X. Xia, C. O’Morain, J. Lelwala-Guruge, F. Ascencio, Å. Ljungh, T. Wadström, Martina Ringnér, Kaija Valkonen, Marianne Paulsson, Åsa Ljungh, Torkel Wadström, I. Guldvog, T. Tannaes, G. Bukholm, H. Grav, R. Corinaldesi, A. Tucci, V. Stanghellini, S. Gasperoni, O. Varoli, G. F. Paparo, M. Gaetani, G. Cioffi, L. Barbara, M. O. Husson, D. Legrand, J. Mazurier, C. Caron, H. Leclerc, G. Spik, L. English, C. T. Keane, C. A. O’Morain, J. G. Fox, P. Correa, N. S. Taylor, N. Fatela, J. Melo Cristino, L. Monteiro, F. Ramalho, A. Saragoça, M.J Salgado, F. Mauch, G. Bode, H. Ditschuneit, P. Malfertheiner, M. Nilius, M. Pugliese, M. Moshkowitz, A. Gorea, M. Santo, S. Berger, T. Gilat, A. Belluzzi, D. Vaira, M. Campieri, S. Boschi, P. Gionchetti, P. Mulè, C. Brignola, F. Rizzello, M. Miglioli, H. Lamouliatte, D. Brugmann, R. Cayla, P. H. Bernard, F. Mégraud, A. Quinton, W. Bär, S. Wagner, E. Glen-Calvo, H. Koopmann, A. Szentmihalyi, Z. Radnai, Gy. Molnar, A. Bálint, and M. Ihász
Subjects: General Medicine
Published: 1992

45. Abstract form for the Irish Journal of Medical Science v workshop on gastroduodenal pathology and Helicobacter pylori July 5th — 7th 1992 — Dublin, Ireland

Author: R. P. H. Logan, P. A. Gummett, M. M. Walker, Q. N. Karim, J. H. Baron, J. J. Misiewicz, G. Trieber, S. Walker, U. Klotz, A. Lozniewski, M. Weber, J. D. de Korwin, J. Floquet, M. C. Conroy, J. C. Burdin, G. A. Mannes, E. Bayerdörffer, W. Höchter, J. Weingart, W. Heldwein, A. Sommer, S. Müller-Lissner, W. Bomschein, S. Miehlke, M. Weinzierl, G. Ruckdeschel, H. von Wulffen, W. Köpcke, M. Stolte, S. J. Rune, T. Justesen, J. M. Hansen, T. G. Jensen, J. Eriksen, O. ø. Thomsen, J. Scheibel, O. Bonnevie, A. Bremmelgaard, M. Vilien, S. Knuhtsen, L. Elsborg, J. Hansen, K. Lauritsen, H. R. Wulff, D. Boixeda, S. Ballestero, R. Cantón, L. De Rafael, C. Martinm de Argila, M. J. Pozuelo, J. Sampedro, F. Baquero, P. Ya. Grigoriev, V. A. Isakov, E. P. Iakovenko, A. M. Hirschl, G. Brandstätter, B. Dragosics, E. Hentschel, M. Kundi, M. L. Rotter, K. Schütze, M. Taufer, M Neri, D Susi, I Bovani, R Pindo, F. Cuccurullo, L. G. V. Coelho, M. C. F. Passos, Y. Chausson, W. L. S. Vieira, F. J. Castro, J. M. M. Franco, M. L. M. Fernandes, L. P. Castro, C. Jonas, E. De Koster, M. Van Gossum, M. Depierreux, M. Cheval, M. Deltenre, E. Schütz, B. Bethke, A. Lee, E. Hegedus, J. O’Rourke, H. Larsson, S. Sjöstedt, B. Veress, C. E. Nord, G. M. Sobala, R. George, D. Tompkins, J. Finlay, A. Manning, S. Sant, H. X. Xia, M. Daw, J. Gilvarry, C. T. Keane, C. O’Morain, M. A. Rubio, B. Hegarty, A. L. Blum, E. Sulser, O. Stadelmann, N. Munoz, E. Buiatti, J. Vivas, W. Oliver, E. Cano, S. Peraza, D. Castro, V. Sanchez, O. Andrade, M. Benz, G. L. Mendz, S. L. Hazell, K. S. Salmela, R. P. Roire, J. Hook-Nikanne, T. U. Kosunen, M. Salaspur, C. J. Luke, D. D. J. Reynolds, C. W. Penn, G. Bode, F. Mauch, H. Ditschuneit, P. Malfertheiner, Richard L. Ferrero, Labigne Agnes, K. A. Eaton, S. Krakowka, H. L. T. Mobley, Li-Tai Hu, P. A. Foxall, A. P. Moran, I. M. Helander, C. Altman, I. Sobhani, C. Vissugaire, M. Migrant, J. P. Etienne, P. Sommi, V. Ricci, R. Fiocca, E. Cova, N. Figura, M. Romano, K. J. Ivey, E. Solcia, U. Ventura, M. Nilius, S. Schieffer, K. J. Hengels, H. Jablonowski, G. Strohmeyer, M. D. Cabrai, A. J. A. Barbosa, G. F. Lima Hr., C. A. Oliveira, J. M. Polak, G. Oderda, L. Villani, F. Altare, I. Morra, L. Miserendino, N. Ansaldi, M. F. Dixon, J. I. Wyatt, A. T. R. Axon, S. Beattie, H. Hamilton, S. Shabib, E. Cutz, B. Drumm, P. Sherman, L. A. Noach, T. Rolf, N. B. Bosma, M. P. Schwartz, J. Oosting, E. A. J. Rauws, G. N. J. Tytgat, A. Andrew, G. Nardone, F. d’Ormiento, M. Pontillo, A. J. Lobo, J. S. Uff, C. N. M. McNulty, S. P. Wilkinson, R. Suriani, C. Pallante, M. Ravizza, D. Galliano, D. Sallio, M. Malandrino, R. Oneglio, M. Colozza, D. Mazzucco, E. Gaia, S. Eidt, P. Vincent, F. Gottrand, D. Turck, M. Lecomte-Houcke, H. Leclerc, F. Bonvicini, S. Pretolani, M. Baraldini, D. Cilla, S. Baldinelli, E. Bazocchi, P. Acampora, N. Careddu, E. Brocchi, G. Gasbarrini, M. Joubert, N. Bazin, D. Thiaucourt, E. Protte, C. Gissler, A. Duprez, P. Merlin, S. Forestier, J. Labenz, E. Gyenes, G. H. Rühl, G. Börsch, G. Daskalopoulos, J. Carrick, R. Lian, S. Wagner, J. Bleck, M. Gebel, W. Bär, M. Manns, H. Lamouliatte, P. H. Bernard, R. Cayla, G. Vialette, A. Quinton, F. Mégraud, M. Lemaire, A. Quinten, A. De Mascarel, P. Webb, D. Forman, T. Knight, A. Wilson, S. Graves, D. Newell, J. Elder, E. Tonelli, M. R. A. Gatte, G. C. Ghironzi, G. Giulianelli, K. B. Bamford, J. S. A. Collins, J. Bickley, B. T. Johnston, S. Potts, V. Boston, R. J. Owen, J. Sloan, L. Basso, S. Lawlor, J. Clune, H. Szelényi, G. Stohmeyer, G. Macedo, I. Iglésias, A. P. Chaves, A. Loureiro, P. H. Katelaris, F. Seow, B. Lin, J. Napoli, D. B. Hones, M. C. Ngu, Natalia S. Akopyantz, Nikolay O. Bukanov, T. Ulf Westblom, Douglas E. Berg, J. F. Nyst, P. Denis, M. Buset, M. De Reuck, H. Nielsen, L. P. Andersen, Sabine Birkholz, Ulrich Knipp, Claudia Nietzki, Wolfgang Opferkuch, J. E. Crabtree, P. Peichl, I. J. D. Lindly, K. Deusch, C. Seifirth, A. Funk, I. Dahie, K. Reut, M. Classen, P. Gionchetti, D. Vaira, M. Campieri, E. Bertinelli, M. Menegatti, A. Belluzzi, C. Briognola, M. Miglioli, L. Barbara, A. Di Tommaso, M. T. De Magistris, M. Bugnoli, R. Petracca, A. Covacci, S. Censini, R. Rappuoli, S. Abrignani, M. C. Territo, K. L. Smela, J. R. Reeve, T. D. Lee, J. H. Walsh, D. Armellini, Z. Y. Xiang, H. M. Mitchell, P. J. Hu, Y. Y. Li, Z. J. Wang, S. M. Zhao, Q. Liu, M. Chen, G. G. Du, M. I. Filipe, P. I. Reed, M. E. Craanen, P. Blok, W. Dekker, E. Colombo, D. Redaelli, M. Santangelo, M. Spinelli, F. Farinati, F. Valiante, G. Delia Libera, B. Germanà, R. Baffa, M. Rugge, F. Vianelo, F. Di Mario, Pentti Sipponen, T. Rokkas, G. Popotheodorou, N. Kaldgeropoulos, C. Deprez, P. Galand, J. G. Fox, P. Wishnok, J. C. Murphy, S. Tannenbaum, P. Correa, Julie Parsonnet, C. Macor, G. L. Da Broi, C. Avellinio, R. Reifen, I. Rasooly, M. E. Millson, K. Murphy, J. E. Thomas, E. J. Eastham, E. Malorgio, D. Dell’Olio, T. P. Kemmer, J. E. Dominguez-Munoz, H. Klingel, M. R. A. Gatto, R. Olivieri, R. F. Bayeli, L. Abate, L. De Gregorio, J. Aziz, E. Esposito, C. Basagni, R. Guilluy, M. Rousseau-Tsangaris, J. L. Brazier, Torkel Wadstiöm, Tadeusz Tyszkiewicz, Per Bergenzaun, Karin Olsson, C. Birac, F. Tall, M. Albenque, A. Labigne, F. Megraud, R. A. Feldman, J. Deeks, Y. Glupczynski, A. Burette, H. Goossens, C. Van den Boore, J. P. Butzler, S. Veldhuyzen van Zanten, L. Best, G. Benzanson, D. Haldane, S. Hazell, N. P. Mapstone, D. A. F. Lynch, P. Quirke, D. E. Taylor, N. Chang, M. Eaton, E. Stockdale, S. M. Salama, L. Thompson, A. Cockayne, R. C. Spiller, E. Leen, E. Sweeney, H. Klann, R. Hatz, W. Bornschein, T. Simon, A. Eimiller, F. Bolle, C. Schweikert, W. Köpeke, S. F. Moss, A. E. Bishop, J. Calam, R. J. Cahill, H. Xia, J. Solnick, and L. Tompkins
Subjects: 0303 health sciences, medicine.medical_specialty, biology, 030306 microbiology, business.industry, General surgery, General Medicine, Helicobacter pylori, biology.organism_classification, language.human_language, Duodenal ulcer, 03 medical and health sciences, Irish, language, Medicine, Optometry, Gastritis, medicine.symptom, business, Medical science, 030304 developmental biology
Published: 1992

46. Irish society of gastroenterology

Author: A. Brannigan, N. N. Williams, M. Grahn, N. S. Williams, J. M. Fitzpatrick, P. R. O’Connell, C. V. Soong, P. Blair, M. I. Halliday, J. M. Hood, B. J. Rowlands, A. A. B. Barros D’sa, R. J. Cahill, S. Beattie, H. Hamilton, C. O’Morain, S. J. Kelly, K. E. O’Malley, W. A. Stack, D. O’Donoghue, A. W. Baird, K. J. Cronin, M. J. Kerin, J. Crowe, P. MacMathuna, J. Lennon, T. F. Gorey, A. Chua, V. O’Kane, T. G. Dinan, P. W. N. Keeling, E. Mulligan, K. L. Cronin, P. Dervan, A. Ireland, D. Murphy, G. O’Sullivan, E. Ryan, P. Kelly, J. Gilvarry, S. Sant, X. J. Fan, C. N. Shahi, M. O’Connell, D. G. Weir, D. Kelleher, J. McDevitt, J. M. O’Donoghue, P. G. Horgan, W. J. Byrne, M. McGuire, H. F. Given, M. A. Daw, P. Kavanagh, P. O’Mahony, T. Joy, F. Gleeson, A. Mullan, M. Gibney, Anne Mannion, F. M. Stevens, C. F. McCarthy, A. A. Killeen, P. M. Murchan, J. V. Reynolds, N. Leonard, P. Marks, F. B. V. Keane, W. A. Tanner, M. A. O’Connell, B. Corridan, R. Collins, R. Shannon, R. Cahill, W. P. Joyce, M. Goggin, J. Hyland, O. Traynor, A. Qureshi, M. DaCosta, N. Brindley, P. Burke, P. Grace, D. Bouchier-Hayes, A. L. Leahy, G. Courtney, H. Osbome, N. O’Donovan, M. O’Donoghue, J. K. Collins, D. Morrissey, J. E. McCarthy, H. P. Redmond, A. D. K. Hill, P. A. Grace, H. Naama, O. M. Austin, D. M. Bouchier-Hayes, J. M. Daly, D. Breslin, C. P. Delaney, S. T. O’Sullivan, G. C. O’Sullivan, W. O. Kirwan, C. D. Weir, L. T. McGrath, S. Maynard, N. H. Anderson, C. Gokulan, T. A. O’Gorman, E. Breshihan, Pin Yin Lam, R. Skehill, H. Grimes, J. A. McKeever, M. A. Stokes, D. Mehigan, T. V. Keaveny, J. Meehan, A. Molloy, C. Q’Farrelly, J. Scott, M. S. Dudeney, A. Leahy, P. A. Grace., G. McEntee, N. D. Hcaton, V. Douglas, R. Mondragon, J. O’Grady, R. Williams, K. C. Tan, H. X. Xia, C. T. Keane, C. A. O’Morain, A. O’Mahony, A. Corbett, P. Harte, H. Mulcahy, S. Patchett, W. Stack, M. Gallagher, K. Connolly, J. Doyle, J. R. Flynn, M. Maher, D. Hehir, A. Horgan, R. Stuart, M. P. Brady, P. W. Johnston, B. T. Johnston, B. J. Collins, J. S. A. Collins, A. H. G. Love, S. G. Marshall, T. G. Parks, R. A. J. Spence, H. J. O’Connor, K. Cunnane, M. Duggan, P. MacMalhuna, M. Kerin, S. E. A. Attwood, L. Viani, M. Jeffers, T. N. Walsh, P. J. Byrne, I. Frazer, T. P. J. Hennessy, G. L. Hill, W. Dickey, S. A. McMillan, C. Bharucha, K. G. Porter, H. Rolfe, J. Thornton, J. Coleman, R. B. Stephens, S. Hone, K. Holmes, I. P. Kelly, T. P. Corrigan, D. McCrory, M. McCaigue, G. R. Barclay, M. Quirke, J. E. Hegarty, D. P. O’Donoghue, D. O’Hanlon, and J. Byrne
Subjects: medicine.medical_specialty, Irish, business.industry, Ophthalmology, language, Medicine, Library science, General Medicine, business, language.human_language
Published: 1992

47. The effect of colonic site of biopsy on cell proliferation profiles using BRDU incorporation as a measure of cell proliferation

Author: C. O'morain, P. M. Mathias, K. R. O'sullivan, and S Beattie
Subjects: Adenoma, Adult, Cancer Research, Pathology, medicine.medical_specialty, Colon, Epidemiology, Colorectal cancer, medicine.drug_class, Colonic Polyps, Colonoscopy, Cell Count, Monoclonal antibody, chemistry.chemical_compound, Colon, Sigmoid, Biopsy, medicine, Humans, Intestinal Mucosa, Aged, Cell Nucleus, medicine.diagnostic_test, Cell growth, business.industry, Significant difference, Rectum, Public Health, Environmental and Occupational Health, Antibodies, Monoclonal, Middle Aged, medicine.disease, digestive system diseases, Bromodeoxyuridine, Oncology, chemistry, Immunohistochemistry, business, Cell Division
Abstract: Sigmoidal and rectal biopsies were taken from 10 patients at colonoscopy. Colonic crypt cell proliferation was measured using a monoclonal antibody to bromodeoxyuridine by an immunohistochemical technique. Labelling index and crypt cell proliferation profiles were analysed and compared between the two sites. No statistically significant difference was found in proliferation parameters. Assessment of colonic proliferation is a useful indicator for colorectal cancer risk and for determining the effects of ongoing drug treatment. Rectal biopsies are easier to take than sigmoidal biopsies. The results of this study suggest that there is no difference in cell proliferation at the two sites. Rectal biopsies are more practical for clinical studies.
Published: 1992

48. Irish association of rheumatology&rehabilitation

Author: J. O’Byrne, S. Eustace, M. M. Stephens, M. N. M. R. Farahat, G. Yanni, R. Posten, G. S. Panayi, S. Sant, R. Costello, M. Barry, J. Hassan, C. Feighery, B. Bresnihan, A. Whelan, F. Coakley, A. M. de Paor, R. B. Reilly, E. B. Casey, V. J. Tormey, G. Kearns, K. Gaffney, P. J. Freyne, M. Callaghan, O. FitzGerald, D. Veale, E. O’Nuallain, D. Reen, M. Farrell, S. Rogers, L. Barnes, R. J. Coughlan, C. McCarthy, M. McDermott, D. Hourihane, C. O'Morain, S. O'Reilly, P. Hartley, E. Casey, L. Clancy, F. Mulcahy, N. Hall, A. Murphy, C. Breen, D. Kelleher, M. Abuzakouk, and C. O'Farrelly
Subjects: medicine.medical_specialty, Rehabilitation, business.industry, medicine.medical_treatment, Association (object-oriented programming), General Medicine, Rheumatology, language.human_language, Irish, Internal medicine, medicine, language, Physical therapy, business
Published: 1992

49. Irish society of gastroenterology

Author: L. A. Cotter, M. Healy, M. Buckley, C. O’Morain, C. Keane, R. R. O’Moore, W. Dickey, G. Roberts, G. Orr, K. Porter, D. McCrory, M. I. Halliday, M. Hoper, A. Crockard, B. J. Rowlands, A. Chua, T. Dinan, B. Dunbar, D. G. Weir, P. W. N. Keeling, B. T. Johnston, J. S. A. Collins, R. J. McFarland, A. H. G. Love, A. Darzi, C. T. N. Speakman, A. Spigelman, M. M. Henry, W. A. fnTanner, G. P. fnMcEntee, F. B. fnKeane, O. Tighe, M. Bennett, H. Mulcahy, N. N. Williams, J. P. Duignan, D. Bouchier-Hayes, D. O’Donoghue, D. T. Croke, A. D. Hill, T. N. Walsh, T. P. J. Hennessy, M. Goggin, W. P. Joyce, C. Prendergast, E. Gibney, O. J. Traynor, J. Hyland, S. O’Brien, M. X. Fitzgerald, J. E. Hegarty, A. Leahy, P. Grace, A. Qureshi, M. Leader, P. Broe, S. Eustace, N. Blake, J. McDevitt, C. F. Feighery, C. O’Farrelly, D. Kelleher, M. A. O’Connell, M. A. Stokes, G. L. Hill, P. Gaffney, J. O’Leary, C. Doyle, J. Hogan, Anne Gaffney, S. E. A. Attwood, P. Murphy, R. B. Stephens, R. H. Wilson, R. Gilliland, F. Kee, J. M. Sloan, R. J. Moorehead, G. ’Suilleabhain, A. Horgan, W. O. Kirwan, G. T. Deans, M. Heatley, K. Williamson, T. G. Parks, B. J. Rowland, R. A. J. Spence, K. Mealy, P. Burke, M. Herlyn, H. P. Redmond, A. P. Clery, J. M. Deasy, O. Austin, J. Meenan, R. J. Canili, P. M. Mathias, S. Beattie, H. Hamilton, J. G. Geoghegan, C. A. Cheng, D. C. Lawson, T. N. Pappas, R. Collins, S. Beatie, J. K. Collins, G. O’Sullivan, A. Corbett, W. D. B. Clements, P. MacMathuna, M. Lombard, A. Gimson, D. Westaby, R. Williams, M. Duggan, J. Lennon, J. Crowe, A. J. Ritchie, F. Johnston, J. McGuigan, J. R. P. Gibbons, K. D. Buchanan, J. M. Gilvarry, R. Robinson, J. F. Fielding, M. Lawler, P. Humphries, O. Sheils, D. S. O’Briain, J. McCarthy, M. McDermott, D. Hourihane, H. Gallagher, M. Barry, F. Lennon, W. P. Hederman, P. R. O’Connell, T. F. Gorey, J. M. Fitzpatrick, J. M. Daly, J. E. Carthy, H. Redmond, D. Croake, P. A. Grace, G. Campbell, O. Maguire, S. Lynch, J. Atwood, L. Madrigal, J. Attwood, A. Murphy, P. Shovlin, J. Hegarty, V. Egleston, D. P. MacErlean, S. Johnston, K. O’Malley, G. McEntee, E. Smyth, B. Moran, G. Plant, M. Rees, N. Brindley, H. Osborne, B. Lane, G. Lynch, J. Geraghty, D. Murphy, M. O’Brien, and P. Harte
Subjects: Irish, business.industry, language, Library science, Medicine, General Medicine, business, language.human_language
Published: 1992

50. Irish Society of Gastroenterology

Author: W. J. Campbell, T. G. Parks, R. A. J. Spence, N. C. Nevin, S. Jazrawi, T. N. Walsh, P. J. Byrne, H. Li, T. P. J. Hennessy, A. D. K. Hill, C. Bolger, E. J. Prendiville, A. Corbett, G. O’Sullivan, J. K. Collins, M. O’Sullivan, S. Nolan, M. O’Donoghue, Brenda O’Donoghue, D. McCabe, S. O’Brien, J. Dowsett, M. X. Fitzgerald, J. E. Hegarty, L. Madrigal, S. Lynch, D. Kelleher, C. Feighery, D. G. Weir, C. O’Farrelly, J. Meenan, F. Mulcahy, P. W. N. Keeling, H. Mulcahy, S. Patchett, N. Afdhal, D. P. O’Donoghue, M. Toner, I. L. Daly, C. McCarthy, R. Collins, S. Beattie, C. Keane, C. O’Morain, N. McEniff, S. Hamilton, M. D. O’Donnell, N. P. Nolan, E. Foster-Smith, K. F. McGeeney, G. Burke, W. P. Joyce, P. V. Delaney, K. F. Choo, F. M. Stevens, M. Maher, R. Waldron, M. T. P. Caldwell, P. Murchan, W. Beesley, T. M. Feeley, W. A. Tanner, F. V. B. Keane, M. A. Stokes, G. L. Hill, H. J. O’Connor, P. L. Redmond, W. Dickey, R. G. P. Watson, K. G. Porter, H. X. Xia, M. A. Daw, C. T. Keane, C. A. O’Morain, K. R. Gardiner, N. H. Abderson, M. D. McCaigue, P. J. Erwin, M. I. Halliday, B. J. Rowlands, S. E. A. Attwood, K. Mealy, J. McGrath, F. Abbasakoor, R. B. Stephens, P. Nicholson, J. Hyland, O. Traynor, I. Grosjean, F. O’Brien, S. T. Irwin, M. Barry, O. J. Traynor, K. C. Tan, E. J. Guiney, J. O’Grady, R. Williams, J. P. McGrath, J. Byrne, D. Timon, C. Armstrong, and D. S. Quill
Subjects: Irish, business.industry, language, Library science, Medicine, General Medicine, business, language.human_language
Published: 1991

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

438 results on '"C. O'Morain"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources